%PDF-1.3
%
5 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 151>>stream
xα0OqhTtUa2$5?)ņ,w
EV({@J =͍|v˙ɄM~`pekZa[٥ Og*cL_y"VŪX9k&C29
endstream
endobj
12 0 obj
<>stream
2020-08-14T08:21:22+05:30
Arbortext Advanced Print Publisher 9.0.114/W
2020-08-24T06:57:57-07:00
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
application/pdf
JAYAO-2020-0100-ver9-Raffone_2P 1..9
uuid:8ccb3dfb-9f04-452b-8f3d-b7b957c78c5a
uuid:37931942-4435-4146-b7f4-99ff34e3acd4
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
32 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 72 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(Although)-332.5(total)-335.4(hysterectomy)-340.5(is)-330.4(considered)-337(the)-332.9(gold)-332.8(stan-)]TJ
-1.0137 -1.1174 TD
[(dard)-356.9(treatment)-360.6(for)-360.3(AEH)-357.6(and)-355.8(endometrial)-362.8(cancer,)-360.2(many)-358.1(pa-)]TJ
0 -1.1116 TD
[(tients)-359.3(need)-363.8(a)-353.6(conservativ)-9.9(e)-353.6(treatment)-366.3(to)-353.7(preserve)-363.4(fertility)-363(or)]TJ
T*
[(to)-353.7(avoid)-352.4(any)-355.8(surgical)-356.8(risk.)-353.3(Conservative)-357.6(treatment)-354.8(includes)]TJ
T*
[(pr)20.9(og)15.1(es)19.9(ti)20.6(ns)-163.3(wi)19.8(th)-157.8(or)-163.4(wi)19.8(th)20.7(ou)20.8(t)-174(h)0(y)20.8(s)0(t)20.9(e)0(r)14(o)0(s)21(c)0(o)19.7(p)0(i)20.7(c)-175(re)19.7(se)19.9(ct)19.5(io)20.7(n,)-165.8(an)19.7(d)-168.1(f)0(o)20.9(l)0(l)14.8(o)0(w)20(-)]TJ
0 -1.1174 TD
[(up)-290.2(biopsies)-286.3(every)-290(36)-285.5(months.)]TJ
7.3823 0 0 6.5614 183.5716 674.7021 Tm
(3,1619)Tj
9.843 0 0 9.843 210.444 670.3369 Tm
[(Such)-287.6(an)-291.3(approach)-288.7(may)]TJ
-15.0789 -1.1116 TD
[(also)-379.9(be)-377.7(adopted)-373(for)-377.6(early)-382.3(endometri)9.3(al)-377.9(cancer)-379.9(\(EEC\))-377.5(in)-376.7(the)]TJ
T*
[(case)-301.4(of)-301.7(endometri)9.3(oid)-302.9(type,)-297.1(tumor)-294.8(grade)-301.5(1,)-298.3(absence)-300.2(of)-295.9(extra-)]TJ
0 -1.1174 TD
[(uterine)-442.2(metastase)7.4(s,)-442.1(and)-442.2(absence)-444.1(of)-439.9(lymphovascula)9.7(r)-444.6(space,)]TJ
0 -1.1116 TD
[(my)19.6(om)19.6(et)19.5(ri)15(al)19.5(,)-205(o)0(r)-192.2(c)0(e)18.5(r)0(v)20.9(i)0(c)13.8(a)0(l)-193.6(i)0(n)20.7(v)0(a)19.7(s)0(i)15.1(o)0(n)20.8(.)]TJ
7.3823 0 0 6.5614 188.9574 630.8786 Tm
(18)Tj
9.843 0 0 9.843 198.3117 626.5132 Tm
[(Se)19.8(ve)19.7(ra)19.7(l)-208.6(o)0(r)20.9(a)0(l)-193.6(o)0(r)-198(i)0(n)20.7(t)0(r)20.7(a)0(u)19.7(t)0(e)13.8(r)0(i)20.7(n)0(e)]TJ
-13.8463 -1.1116 TD
[(proges)-7.5(togens)-341.8(have)-340.8(been)-340.8(used,)-337.1(includ)-8(ing)-337.5(medro)-7.9(xyprog)-6.6(ester-)]TJ
0 -1.1174 TD
[(one)-436.4(aceta)-10.3(te,)-438.9(mege)-8(strol)-437.5(aceta)-10.3(te,)-438.9(noreth)-7.9(indron)-6.7(e)-434.2(aceta)-10.3(te,)-438.9(and)]TJ
0 -1.1116 TD
-.0214 Tc
[(le)-6.4(von)-5.2(or)-5.2(ges)-5(t).4(r)-5.2(e)-.6(l-)-5.2(rel)-5.3(eas)-5(ing)-391.1(i).4(n)-5.2(t).4(r)-5.2(a)-.6(ut)-5.3(eri)-5.3(n).5(e)-392.3(d).5(ev)-5.2(ice)-392.3(\().6(LN)-6.1(G-)-5.2(IUD)-6.1(\)).6(.)]TJ
7.3823 0 0 6.5614 280.1196 597.9967 Tm
-.023 Tc
[(3,18)8.5(,2)8.5(0)]TJ
9.843 0 0 9.843 62.022 582.6896 Tm
0 Tc
[(However,)-487.5(a)-491.8(variable)-490.6(percentage)-489.2(of)-486(conservatively)-486.8(treated)]TJ
T*
[(women)-325.6(shows)-322.8(unfavorabl)9.6(e)-330.6(outcomes,)-321(with)-322.3(no)-324.7(regression)-318.3(of)]TJ
0 -1.1174 TD
[(the)-269.5(disease,)-262(progression)-260.6(to)-267.3(cancer,)-262.3(relapse)-264.5(after)-267.1(a)-267.2(regression,)]TJ
0 -1.1116 TD
[(or)-284.4(failure)-280.9(to)-284.6(achieve)-283.2(pregnancy)-278.3(after)-284.4(treatment.)]TJ
7.3823 0 0 6.5614 249.6188 554.1731 Tm
(21)Tj
9.843 0 0 9.843 259.7669 549.8077 Tm
(Therefore,)Tj
-20.0899 -1.1116 TD
[(great)-439.9(efforts)-440.7(have)-438.7(been)-438.7(made)-439.9(in)-445.8(the)-436.6(search)-441.8(for)-441(predictive)]TJ
0 -1.1174 TD
[(markers)-276(of)-278.6(response)-275.7(to)-278.8(conservative)-277.1(treatment)8(.)]TJ
1.0137 -1.1116 TD
[(Several)-448.9(clinical)-456.3(predictive)-452.6(factors)-453.4(along)-450.3(with)-449(histologi-)]TJ
-1.0137 -1.1116 TD
[(cal,)-279.9(molecular,)-277.5(and)-275.2(imaging)-275.3(modalities)-279.8(have)-277.4(been)-271.7(studied)-279.6(to)]TJ
0 -1.1174 TD
[(better)-596.6(understand)-595(the)-597.8(response)-598.2(to)-589.8(conservative)-599.6(manage-)]TJ
0 -1.1116 TD
[(ment)-341(of)-336.2(AEH)-340.3(and)-338.5(EEC.)]TJ
7.3823 0 0 6.5614 158.9102 488.4093 Tm
(2231)Tj
9.843 0 0 9.843 180.737 484.0439 Tm
[(Among)-335.9(the)-338.7(clinical)-341.1(predictive)]TJ
-12.0608 -1.1116 TD
[(factors)-395.8(of)-393.8(response)-390.9(to)-394(conservative)-398(treatment,)-392.8(age)-397.3(at)-389.4(diag-)]TJ
0 -1.1174 TD
[(nosis,)-452.2(previous)-447.6(pregnancies,)-452.1(obesity,)-450.1(history)-451.2(of)-445.7(infertility,)]TJ
0 -1.1116 TD
[(histology)-344.2(type,)-337.4(the)-344.4(diagnosis)-345(of)-336.2(polycystic)-347.6(ovary)-340.7(syndrome)]TJ
T*
[(\(PCOS\),)-604.8(hormonal)-604.6(therapy,)-601.1(menstrual)-606.8(cycle)-608.1(characteris-)]TJ
T*
[(tics,)-481.4(and)-482.5(diabetes)-478.9(mellitus)-483.8(have)-479(been)-484.8(proposed,)-479.7(but)-475.7(their)]TJ
0 -1.1174 TD
[(usefulness)-427.6(in)-428.5(p)-6.9(r)-12.6(e)-8(d)-12.6(i)-12.7(c)-8(t)-12.7(i)-7(n)-12.6(g)-433.1(t)-12.7(h)-6.9(e)-440(r)-6.8(e)-13.8(s)-6.7(p)-12.6(o)-6.9(n)-12.6(s)-12.4(e)-434.2(t)-7(o)-438.8(t)-7(r)-12.6(e)-13.8(a)-8(t)-12.7(m)-8.1(e)-13.8(n)-6.9(t)-433.2(i)-12.7(s)-432.9(s)-12.4(t)-12.7(i)-7(l)-12.7(l)]TJ
0 -1.1116 TD
.0132 Tc
[(un)6.3(cl)6.2(ea)5.2(r.)]TJ
7.3823 0 0 6.5614 94.3937 411.7038 Tm
.0143 Tc
(22,23,27,3237)Tj
9.843 0 0 9.843 72 396.3968 Tm
0 Tc
[(Identifying)-197.9(risk)-200.1(factors)-205.7(of)-198(treatment)-205.1(failure)-200.3(of)-198(patients)-201.4(with)]TJ
-1.0137 -1.1174 TD
[(AEH)-248.1(and)-252.1(EEC)-248.6(is)-249.8(of)-244.1(paramount)-249.7(importance)-252.1(in)-250(counseling)-249.6(the)]TJ
0 -1.1116 TD
[(patient)-367.5(who)-367(desire)-365.9(conservative)-369.2(management)-369.6(of)-365(these)-364.9(con-)]TJ
T*
[(ditions.)-351.2(The)-345.5(aim)-345.6(of)-347.7(this)-350(study)-345.3(was)-350.7(to)-347.9(determine)-348.9(the)-344.4(role)-351.2(of)]TJ
0 -1.1174 TD
[(several)-183.9(clinical)-185.6(factors)-182.7(in)-180.9(the)-183.1(prediction)-180.7(of)-180.7(treatment)-187.8(failure)-183(in)]TJ
0 -1.1116 TD
[(patients)-299.3(diagnosed)-300.2(with)-299.3(AEH)-300(or)-295.9(EEC)-300.5(undergoing)-300.3(conserva-)]TJ
T*
[(tive)-328.4(management)-329.3(with)-322.3(hysteroscopic)-328.7(resection)-330.2(of)-324.7(the)-327.1(lesion)]TJ
T*
[(and)-280.9(LNG-IUD)-283(insertion.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 62.022 287.2062 Tm
[(Materials)-332.7(and)-338.2(Methods)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 270.7653 Tm
[(The)-380(present)-384.3(study)-379.8(is)-382.3(a)-382.4(single-center)-387.7(retrospective)-382(obser-)]TJ
-1.0137 -1.1116 TD
[(vational)-230.4(study)-230.1(following)-230(a)-226.9(protocol)-229.1(dened)]TJ
/F5 1 Tf
17.4116 0 TD
[(a)-225.7(priori)]TJ
/F4 1 Tf
3.0584 0 TD
[(,)-228.1(reported)]TJ
-20.47 -1.1174 TD
[(following)-310.6(the)-309.9(Strengthening)-310.6(the)-304.1(Reporting)-311.8(of)-307.4(Observational)]TJ
0 -1.1116 TD
[(Studies)-285.2(in)-278.8(Epidemiology)-282.2(\(STROBE\))-284.6(guidelines.)]TJ
7.3823 0 0 6.5614 253.1338 242.2488 Tm
(38)Tj
9.843 0 0 9.843 72 226.9417 Tm
[(The)-305.2(medical)-306.4(records)-309.3(and)-304(pathology)-305.1(reports)-308.2(of)-307.4(all)-304.2(consec-)]TJ
-1.0137 -1.1116 TD
[(utive)-300.7(patients)-305.1(up)-301.7(to)-296.1(45)-301.7(years)-301.3(of)-301.7(age)-305.1(diagnosed)-300.2(with)-299.3(AEH)-305.7(or)]TJ
0 -1.1174 TD
[(ECC)-409.7(who)-413.1(underwent)-410.6(conservative)-415.3(treatment)-412.4(with)-414.5(hystero-)]TJ
0 -1.1116 TD
[(scopic)-561.8(resection)-566.4(followed)-558.2(by)-560.9(LNG-IUD)-565.3(insertion)-558.4(at)-562.2(the)]TJ
T*
[(Department)-483.4(of)-480.2(Neuroscience,)-484(Reproductive)-484.5(Sciences,)-483.2(and)]TJ
0 -1.1174 TD
[(Dentistry)-213.7(or)-209.5(at)-210.8(the)-211.9(Department)-218.4(of)-209.5(Public)-215.2(Health)-211.7(of)-209.5(University)]TJ
0 -1.1116 TD
[(Federico)-300.2(II)-290.1(\(Naples,)-302.2(Italy\),)-293.6(from)-293.5(January)-297.8(2007)-292.4(to)-296.1(June)-293.4(2018)]TJ
T*
[(were)-577.8(reviewed)-583.5(for)-573.4(assessing)-581.8(the)-574.8(associations)-581(of)-578.1(several)]TJ
0 -1.1174 TD
[(clinical)-427.5(factors)-424.6(with)-426(the)-419.3(response)-425.4(to)-422.8(treatment.)-427.4(Additional)]TJ
0 -1.1116 TD
[(data)-335.2(were)-335.9(obtained)-333.9(by)-330.5(administrating)-336.2(a)-330.6(telephone)-336.2(question-)]TJ
T*
[(naire)-284.4(to)-278.8(each)-284.4(included)-282.1(patient.)]TJ
1.0137 -1.1174 TD
[(Exclusion)-283(criteria)-283.3(were)-284(the)-281.1(following:)]TJ
-.1037 -1.7164 TD
[(-)-335.1(patients)-339.6(treated)-334(with)-333.8(hysterectomy;)]TJ
0 -1.1174 TD
[(-)-335.1(follow-up)-333.5(period)]TJ
/F6 1 Tf
7.8447 0 TD
(<)Tj
/F4 1 Tf
.5529 0 TD
[(1)-335.2(year;)]TJ
-8.3977 -1.1116 TD
[(-)-317.8(absence)-323.2(of)-318.9(written)-315.4(informed)-322.3(consent)-321(for)-314.3(the)-321.4(use)-315.3(of)-318.9(own)]TJ
.9964 -1.1116 TD
[(biospecimens)-334.6(for)-337.3(research)-335.7(purposes;)]TJ
24.5133 67.9242 TD
[(-)-444.6(missing)-452.3(data)-450.4(after)-451.4(review)-453.4(of)-445.7(the)-453.8(medical)-450.4(records)-453.3(and)]TJ
.9907 -1.1174 TD
[(unable)-256.7(to)-250(obtain)-255.7(the)-252.3(information)-256.7(after)-255.6(completion)-256.9(of)-255.6(the)]TJ
0 -1.1116 TD
[(telephone)-336.2(questionnaire.)]TJ
-.8928 -2.2233 TD
[(The)-374.3(preoperative)-380.9(management,)-373(treatment,)-375.5(and)-373.1(follow-up)]TJ
-1.0137 -1.1174 TD
[(protocol)-315.5(of)-307.4(these)-313(conditions)-311.9(at)-308.8(our)-308.5(institution)-312.2(had)-309.7(been)-312(pre-)]TJ
0 -1.1116 TD
[(viously)-284.2(reported.)]TJ
7.3823 0 0 6.5614 380.2393 663.7605 Tm
(18)Tj
9.843 0 0 9.843 323.0361 648.4534 Tm
[(All)-419.1(the)-419.3(pathology)-420.3(slides)-422.3(were)-416.5(reviewed)-422.2(by)-416.9(two)-419(blinded)]TJ
-1.0137 -1.1174 TD
[(authors)-308.3(\(L.I.)-299.3(and)-304(A.T.\))-306(to)-301.8(conrm)-302.6(the)-304.1(initial)-303.3(diagnosis.)-308.1(Dis-)]TJ
0 -1.1116 TD
[(agree)-9(ments)-480.1(were)-479.9(resolved)-483.3(by)-480.3(discussion)-478.4(at)-481.5(a)-480.3(two-headed)]TJ
T*
[(microscope)-9.9(.)]TJ
1.0137 -1.1174 TD
[(The)-276.4(primary)-275.1(outcome)-282.1(was)-275.9(the)-275.3(association)-274.8(of)-278.6(each)-272.8(clinical)]TJ
-1.0137 -1.1116 TD
[(factor)-325.8(with)-322.3(treatment)-320.3(failure.)-324.7(Secondary)-324.2(outcomes)-323.3(were)-324.4(the)]TJ
T*
[(associations)-396.7(of)-388.1(each)-393.8(clinical)-393(factor)-394.9(with:)-386.9(\(1\))-389.1(no)-388.1(regression)]TJ
T*
[(of)-319(disease,)-325.4(\(2\))-314.3(relapse)-322.1(of)-319(the)-321.4(disease,)-319.6(or)-318.9(\(3\))-314.3(achieveme)-11.3(nt)-313.4(of)]TJ
0 -1.1174 TD
[(successful)-307.8(pregnancy)-301.4(after)-301.6(treatment.)-300.7(Treatment)-304(failure)-298.2(was)]TJ
0 -1.1116 TD
[(dened)-452.3(as)-446.7(a)-451.5(combined)-450.2(adverse)-448.7(outcome)-454.9(of)-445.7(treatment,)-450.4(in-)]TJ
T*
[(cluding)-377.8(\(1\))-377.6(no)-376.6(regression)-375.9(of)-376.5(disease)-379.6(and)-373.1(\(2\))-377.6(relapse)-379.7(of)-376.5(the)]TJ
0 -1.1174 TD
[(disease.)-273.6(Regression)-267.5(of)-267.1(the)-269.5(disease)-270.1(was)-270.1(dened)-268(as)-262.4(absence)-271.4(of)]TJ
0 -1.1116 TD
[(any)-315.5(pretreatment)-318.9(lesions)-319.8(\(AEH)-312.6(or)-319(EEC\))-313.1(in)-313.3(two)-315.3(consecutive)]TJ
T*
[(histological)-407.7(examination)-408.9(performed)-405(at)-406.7(the)-402(3-)-405.3(and)-401.9(6-month)]TJ
0 -1.1174 TD
[(follow-up)-304.7(hysteroscopy)-303.2(with)-305(endometrial)-299.4(biopsies)-303.6(under)-300.4(di-)]TJ
0 -1.1116 TD
[(rect)-306.3(visualization.)-303.9(Relapse)-305.9(of)-295.9(the)-304.1(disease)-298.9(was)-304.6(dened)-302.5(as)-302.7(the)]TJ
T*
[(presence)-289.7(of)-278.6(AEH)-282.7(or)-278.6(EEC)-283.2(after)-284.4(a)-278.7(previous)-286.3(regression.)]TJ
1.0137 -1.1174 TD
[(The)-299.4(clinical)-300.8(factors)-297.9(considered)-302.4(in)-296.1(the)-298.3(analysis)-299(of)-295.9(associa-)]TJ
-1.0137 -1.1116 TD
[(tion)-304.2(with)-305(the)-304.1(outcomes)-306.1(of)-307.4(response)-304.5(to)-301.8(treatment)-308.7(were:)-308.3(body)]TJ
T*
[(mass)-449.9(index)-438.8(\(BMI\),)-448.5(cigarette)-446.9(smoking)-440.9(habit,)-448.1(hypertension,)]TJ
T*
[(mean)-336.3(age)-328.2(at)-331.8(menarche,)-334.9(mean)-330.5(menstrual)-330.3(cycle)-331.7(length,)-334(mean)]TJ
0 -1.1174 TD
[(menses)-447.5(length,)-443.4(heavy)-445.6(menstrual)-445.5(bleeding)-443.4(with)-443.3(or)-439.9(without)]TJ
0 -1.1116 TD
[(prolon)-6.7(ged)-390.4(menstrual)-399.4(bleeding,)-395(infrequent)-393.7(menst)-7.8(rual)-391.6(bleed-)]TJ
T*
[(ing,)-571.3(frequent)-569.9(menstrual)-566.4(bleeding,)-567.8(irregular)-571.1(nonmenstrual)]TJ
0 -1.1174 TD
[(vaginal)-419.2(bleeding,)-418(vaginal)-419.2(discharge)-416.5(at)-418.2(the)-419.3(time)-416(of)-411.1(biopsy)-6.5(,)]TJ
0 -1.1116 TD
[(history)-215.1(of)-215.3(previous)-211.5(pregnancies)-10.9(,)-210.8(PCOS,)-211(sterility)-218.8(or)-209.5(infertility,)]TJ
T*
[(family)-326(history)-324.5(of)-319(endometrial)-328.2(cancer,)-325.7(family)-320.2(history)-324.5(of)-324.7(leu-)]TJ
0 -1.1174 TD
[(kemia,)-358.2(family)-349(history)-353.3(of)-353.5(thyroid)-353.5(disease,)-354.2(previous)-349.7(personal)]TJ
0 -1.1116 TD
[(hi)14.9(st)20.9(or)20.9(y)-329.4(o)0(f)-319(n)0(o)15.1(n)0(e)19.7(n)0(d)20.8(o)0(m)19.6(e)0(t)19.6(r)0(i)20.7(a)0(l)-320.3(c)0(a)18.5(n)0(c)13.9(e)0(r)-320.1(d)0(i)20.7(a)0(g)19.7(n)0(o)20.8(s)0(i)20.9(s)0(,)-321.1(u)0(s)21(e)-330.6(of)-324.7(or)20.9(al)-320.3(co)19.7(n-)]TJ
T*
[(tr)15(ac)18.5(ep)19.7(ti)20.6(ve)19.7(s,)-286.6(ho)20.8(rm)19.6(on)20.8(e)-296(a)0(d)19.7(m)0(i)19.5(n)0(i)20.7(s)0(t)20.9(r)0(a)14(t)0(i)20.6(o)0(n)-284.4(f)0(o)20.9(r)-294.8(as)19.9(si)20.9(st)20.9(ed)-285.6(re)19.7(pr)15.1(od)20.8(uc)19.7(ti)20.6(ve)]TJ
T*
[(te)13.8(ch)19.7(no)20.8(lo)20.7(gy)-468.7(\(A)20(RT)18.6(\),)-471(pe)19.7(lv)14.9(ic)-470(pa)19.7(in)-468.9(be)19.7(fo)20.9(re)-469.9(en)19.7(do)15.1(m)15(e)0(t)13.8(r)0(i)20.7(a)0(l)-470(b)0(i)20.7(o)0(p)20.8(s)0(y)15.3(,)]TJ
0 -1.1174 TD
[(pa)13.9(th)20.7(ol)20.7(og)20.8(y)-525.2(d)0(i)20.7(a)0(g)19.7(n)0(o)20.8(s)0(i)15.1(s)-519.3(\(A)20(EH)-516.9(or)-514.8(EE)18.5(C\))19.8(,)-521.8(a)0(n)19.7(d)-519.5(me)18.4(an)-516(le)19.5(ng)20.8(th)-514.9(of)]TJ
0 -1.1116 TD
[(th)15(er)19.7(ap)19.7(y.)-165.8(A)-174.8(d)0(e)19.7(t)0(a)13.8(i)0(l)20.6(e)0(d)-164.6(d)0(e)19.7(s)0(c)14.1(r)0(i)20.7(p)0(t)20.7(i)0(o)20.7(n)-179.6(of)-163.4(th)20.7(e)-175.1(c)0(l)13.8(i)0(n)20.7(i)0(c)19.6(a)0(l)-164.8(f)0(a)14(c)0(t)19.5(o)0(r)20.9(s)-173.7(as)-170.2(de)19.7(n)21(ed)]TJ
T*
[(at)-222.4(th)20.7(e)-226.9(t)0(i)20.6(m)0(e)-223.5(o)0(f)-215.3(d)0(i)20.7(a)0(g)19.7(n)0(o)20.8(s)0(i)15.1(s)-225.5(is)-221(re)19.7(po)20.8(rt)20.7(ed)-216.5(in)-221.2(Su)21(pp)20.8(le)19.6(me)18.4(nt)14.9(ar)19.7(y)-225.7(D)0(a)18.8(t)0(a)-216.6(S)0(1)15.2(.)]TJ
1.0137 -1.1174 TD
[(The)-201.5(potential)-202.8(associations)-206.6(between)-208(each)-203.7(clinical)-202.9(factor)-204.8(and)]TJ
-1.0137 -1.1116 TD
[(each)-370.8(outcome)-362.7(of)-365(response)-362.1(to)-365.2(conservative)-369.3(treatment)-366.3(\(treat-)]TJ
T*
[(ment)-444.7(failure,)-445.6(no)-445.7(regression,)-442.7(relapse,)-446.5(successful)-451.8(pregnancy)]TJ
0 -1.1174 TD
[(after)-439.9(treatment\))-442.3(were)-439.5(initially)-438.1(assessed)-437.7(with)-437.5(standard)-443(uni-)]TJ
0 -1.1116 TD
[(variate)-397.3(analyses:)-393.4(chi-squared)-395.6(test)-391.5(for)-389.1(categorica)-11.3(l)-387.1(variables,)]TJ
/F5 1 Tf
T*
(t)Tj
/F4 1 Tf
.2822 0 TD
[(-test)-375.3(and)-378.8(KruskalWallis)-378.1(test)-374.3(for)-371.9(normally)-380.1(distributed)-376.4(and)]TJ
-.2822 -1.1174 TD
[(non-normally)-361.4(distributed)-353.4(continuous)-357.8(variables,)-356.7(respectively)]TJ
0 -1.1116 TD
[(\(distri)-7.8(bution)-277.6(was)-281.6(assessed)-288(with)-282(ShapiroWilk)-281.8(test\).)]TJ
1.0137 -1.1116 TD
[(The)-293.6(potential)-295(independent)-292.4(predictors)-295.6(of)-295.9(response)-292.9(to)-290.3(treat-)]TJ
-1.0137 -1.1116 TD
[(ment)-289.2(were)-284(then)-282.2(evaluated)-285.5(using)-287.7(multivariate)-283.5(logistic)-286.8(regres-)]TJ
0 -1.1174 TD
[(sion.)-197.8(Covariates)-199.9(were)-197.6(selected)-197.8(for)-193.3(inclusion)-201.3(in)-192.4(the)-194.7(nal)-195.6(model)]TJ
0 -1.1116 TD
[(using)-258.9(a)-249.9(stepwise)-259.5(forward)-251.6(process)-257.3(with)-253.2(the)-252.3(following)-258.8(criteria:)]TJ
T*
(\(1\))Tj
/F5 1 Tf
1.4572 0 TD
(p)Tj
/F4 1 Tf
.5011 0 TD
(-value)Tj
/F6 1 Tf
2.7992 0 TD
(<)Tj
/F4 1 Tf
.5529 0 TD
[(0.05)-289(at)-291.5(univariate)-291.3(analysis,)-296.7(and)-286.7(\(2\))-291.2(clinical)-295(rel-)]TJ
-5.3104 -1.1174 TD
[(evance.)-325.7(To)-325.9(reduce)-321.1(the)-327.1(potential)-323.8(overtting)-323.4(due)-321.3(to)-324.9(the)-321.4(small)]TJ
0 -1.1116 TD
[(number)-354.6(of)-353.5(successes)-359.4(\(dened)-349.7(as)-354.5(treatment)-354.8(failure\),)-354.6(a)-353.6(mini-)]TJ
T*
[(mum)-437.7(events-to-variable)-446.3(ratio)-438.9(of)-434.1(10)-434.2(was)-442.9(maintained)-436.6(in)-440.1(all)]TJ
0 -1.1174 TD
[(phases)-187.1(of)-180.7(model)-180.8(building;)-183.2(Schoenfelds)-183.5(test)-184.2(was)-183.7(carried)-184(out)-176.2(to)]TJ
0 -1.1116 TD
[(check)-671.4(the)-661.2(validity)-667.1(of)-658.8(proportional)-665.6(hazar)-9(ds)-658.6(assumption.)]TJ
T*
[(A)-186.3(standard)-183.8(power)-180.3(analysis)-183.8(for)-181.8(sample)-182.9(size)-185.2(calculation)-184.3(was)-183.7(not)]TJ
0 -1.1174 TD
[(performed,)-391.2(as)-389.1(most)-385.7(clinical)-387.2(factors)-390(considered)-388.8(had)-384.6(not)-389.3(yet)]TJ
0 -1.1116 TD
[(been)-283.2(assessed)-288(in)-278.8(the)-281.1(literature.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(2)Tj
46.2711 0 TD
[(RAFFONE)-336.8(ET)-338.7(AL.)]TJ
ET
endstream
endobj
42 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 69.7323 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(As)-233.3(a)-232.6(separate)-238(additional)-232.7(analysis,)-233.3(the)-235(relationship)-234.7(between)]TJ
-1.0137 -1.1174 TD
[(pathology)-310.8(diagnosis)-304.7(\(AEH)-312.6(or)-301.7(EEC\))-313.1(and)-304(each)-307.4(clinical)-312.3(factor)]TJ
0 -1.1116 TD
[(and)-304(treatment)-303(outcome)-299.4(\(treatment)-304(failure,)-301.6(no)-301.7(regression,)-298.7(re-)]TJ
T*
[(lapse,)-385.6(successful)-388.4(pregnancy)-387.8(after)-388(treatment\))-390.4(was)-385.3(evaluated)]TJ
T*
[(comparing)-313.1(the)-315.6(distribution)-307.4(of)-313.2(all)-310(outcomes)-311.8(and)-309.7(clinical)-318.1(fac-)]TJ
0 -1.1174 TD
[(tors)-280.8(in)-284.6(women)-279.5(with)-282(AEH)-282.7(and)-280.9(in)-278.8(those)-283.1(with)-282(EEC.)]TJ
1.0137 -1.1116 TD
(A)Tj
/F5 1 Tf
1.0367 0 TD
(p)Tj
/F4 1 Tf
.5011 0 TD
[(-value)-325.8(of)]TJ
/F6 1 Tf
3.9857 0 TD
(<)Tj
/F4 1 Tf
.5529 0 TD
[(0.05)-317.8(was)-321.9(considered)-325.4(signicant)-324.4(for)-320(all)-321.5(an-)]TJ
-7.0902 -1.1116 TD
[(alyses,)-190.7(which)-186.2(were)-186.1(carried)-184.1(out)-187.7(using)-184(Stata,)-184.2(version)-187.3(13.1)-185.3(\(Stata)]TJ
0 -1.1174 TD
[(Corp.,)-283(College)-282(Station,)-283.2(TX;)-282(2013\).)]TJ
1.0137 -1.1116 TD
[(The)-380(present)-384.3(study)-379.8(received)-382.2(approval)-379.9(by)-382.3(the)-379(Institutional)]TJ
-1.0137 -1.1116 TD
[(Review)-258.6(Board)-255.3()50.8(Carlo)-250.8(Roma)-7.8(no)54.3()-254.5(o)0(f)-249.8(the)-252.3(University)-260.9(of)-249.8(Naples)]TJ
0 -1.1174 TD
[(Federico)-242.6(II.)-241.7(All)-240.6(included)-241.8(patients)-241.7(signed)-243.9(an)-239.5(informed)-241.7(written)]TJ
0 -1.1116 TD
[(consent)-361.3(for)-354.6(the)-350.2(use)-355.6(of)-359.3(their)-352.5(biospecimens)-357.6(for)-354.6(research)-358.8(pur-)]TJ
T*
[(poses,)-297.7(and)-292.4(all)-292.7(data)-294.8(were)-295.6(anonymized)-298.1(to)-290.3(prevent)-298.1(the)-292.6(identi-)]TJ
T*
[(cation)-285.7(of)-278.6(the)-281.1(subjects.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 552.529 Tm
(Results)Tj
/F10 1 Tf
0 -1.8336 TD
[(Patient)-337.7(characteristics)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 519.6471 Tm
[(A)-318.7(total)-318.1(of)-318.9(43)-319(patients)-322.4(meeting)-322.5(the)-315.6(inclusion)-322.3(criteria)-323.6(were)]TJ
-1.0137 -1.1174 TD
[(included)-316.7(in)-313.3(this)-315.5(study:)-311.9(37)-313.2(\(86%\))-311.8(were)-312.8(diagnosed)-317.4(with)-316.6(AEH)]TJ
0 -1.1116 TD
[(and)-298.2(6)-300.6(\(14%\))-300.3(with)-299.3(EEC.)-298.2(The)-299.4(mean)-301.7(age)-299.4(was)-298.9(36.0)]TJ
/F6 1 Tf
19.6636 0 TD
()Tj
/F4 1 Tf
.72 0 TD
[(5.7)-293.6(years.)]TJ
-20.3836 -1.1116 TD
[(The)-478(mean)-474.5(BMI)-471.7(was)-477.4(28.5)]TJ
/F6 1 Tf
10.9895 0 TD
()Tj
/F4 1 Tf
.72 0 TD
[(7.6)-166.9(kg/m)]TJ
7.3823 0 0 6.5614 209.2535 491.1306 Tm
(2)Tj
9.843 0 0 9.843 212.9385 486.7652 Tm
[(.)-470(Personal)-477.4(history)-474.3(of)]TJ
-15.5627 -1.1174 TD
[(hypertension)-217.2(was)-218.3(reported)-212.8(by)-215.3(14%)-211.7(of)-215.3(the)-211.9(patients,)-216.4(39.5%)-210.5(had)]TJ
0 -1.1116 TD
[(previous)-511(pregnancies,)-509.7(16.7%)-504.2(had)-505.6(the)-505.7(personal)-506.4(history)-503.1(of)]TJ
T*
[(PCOS)-311.3(diagnosis,)-302.4(and)-309.7(7.1%)-301.5(reported)-310.7(personal)-304.8(history)-307.2(of)-301.7(ste-)]TJ
0 -1.1174 TD
[(rility)-254.8(or)-249.8(infertility.)-253.6(Family)-256.8(history)-249.6(of)-255.6(endometrial)-253.3(cancer)-253.1(was)]TJ
0 -1.1116 TD
[(present)-200(in)-198.2(9.3%)-192.1(of)-198(the)-194.7(patients,)-199.1(23.3%)-199(reported)-195.5(family)-199.3(history)]TJ
T*
[(of)-301.7(leukemia,)-299.5(and)-298.2(27.9%)-302.6(of)-295.9(thyroid)-301.7(disease.)-302.4(Personal)-298.9(history)]TJ
T*
[(of)-376.5(previous)-378.5(nonendometrial)-383.4(cancer)-379.9(diagnosis)-379.6(was)-379.5(found)-374.1(in)]TJ
0 -1.1174 TD
[(15.4%)-268.1(of)-261.4(the)-263.8(patients,)-268.2(16.7%)-268.1(reported)-264.6(pelvic)-268.4(pain,)-262.6(and)-263.7(4.8%)]TJ
0 -1.1116 TD
[(reported)-448.9(vaginal)-442.3(discharge)-445.3(at)-441.2(the)-442.3(time)-444.8(of)-439.9(the)-442.3(endometrial)]TJ
T*
[(biopsy)-277.2(resulting)-270.4(in)-273(the)-275.3(diagnosis)-270.1(of)-272.9(AEH)-276.9(or)-272.9(EEC.)-269.4(The)-276.4(mean)]TJ
0 -1.1174 TD
[(age)-236(at)-233.9(menarche)-239.3(was)-235.5(11.6)]TJ
/F6 1 Tf
10.4366 0 TD
()Tj
/F4 1 Tf
.7142 0 TD
[(1.2)-236(years,)-235.7(menstrual)-238.1(cycle)-233.8(length)]TJ
-11.1508 -1.1116 TD
(28.8)Tj
/F6 1 Tf
1.918 0 TD
()Tj
/F4 1 Tf
.72 0 TD
[(3.5)-287.9(days,)-291(and)-292.4(menses)-292(length)-290.3(4.6)]TJ
/F6 1 Tf
13.1033 0 TD
()Tj
/F4 1 Tf
.72 0 TD
[(1.3)-287.9(days.)-291(A)-289.9(total)-289.3(of)]TJ
-16.4612 -1.1116 TD
[(33.3%)-273.8(of)-267.1(women)-273.7(reported)-270.4(heavy)-272.8(menstrual)-272.7(bleeding)-270.6(with)-270.5(or)]TJ
0 -1.1174 TD
[(without)-308.5(prolonged)-310.7(menstrual)-313(bleeding,)-308.6(4.8%)-307.3(reported)-310.7(infre-)]TJ
0 -1.1116 TD
[(quent)-283.3(menstrual)-278.5(bleeding,)-279.8(7.1%)-278.5(reported)-281.9(frequent)-281.9(menstrual)]TJ
T*
-.0157 Tc
[(b)-15.7(l)10.8(eedi)-15.7(n)10.8(g,)-318.6(9.5%)-323.1(repor)-15.7(t)10.8(e)-.7(d)-316.3(f)-15.7(r)11(e)-.7(qu)-15.7(e)9.7(n).5(t)-316.4(i)-15.7(r)10.8(r).5(eg)-15.7(u)10.9(l).4(ar)-322(nonme)-15.7(n)9.7(str)-15.7(u)10.9(al)-316.4(v)-15.7(a)9.7(g-)]TJ
T*
[(i)-15.7(n)10.8(al)-264.6(bleed)-15.7(i)10.8(ng.)-266.8(Regar)-15.7(d)10.9(ing)-264.5(t).4(he)-265.6(us)-15.7(e)-249.3(o).5(f)-264.4(o).5(r)-15.7(a)9.8(l)-258.8(c)-15.7(o)9.7(n).5(tr)-15.7(a)9.8(cept)-15.7(i)10.6(ves)-15.7(,)-250.4(29.3%)]TJ
0 -1.1174 TD
-.016 Tc
[(o)-16(f)-409.8(pa)-16(t)9.3(i).1(ent)-16(s)-409.8(ne)-16(v)9.4(e)-1(r)-426(u).2(sed)-426(ora)-16(l)-411.2(c)-1(on)-16(t)10.5(r).2(ac)-16(e)8.3(p).2(tiv)-16(e)9.4(s)-420.1(a)-16(n)9.4(d)-420.3(2)-16(6)10.6(.)-2.1(2%)-421.3(ne)-16(v)9.4(e)-1(r)]TJ
0 -1.1116 TD
[(r)-15.9(e)9.6(ceiv)-15.9(e)9.5(d)-328(horm)-15.9(o)9.5(n).3(e)-329.2(a)-.9(dmi)-15.9(n)10.6(ist)-15.9(r)10.6(atio)-15.9(n)-317.6(for)-328(ART)-15.9(.)-315.4(The)-329.2(1).3(6)-15.9(.)14.1(7)-15.9(%)-312.9(o)-15.9(f)-317.6(the)]TJ
T*
-.0157 Tc
[(p)-15.7(a)9.7(tien)-15.7(t)10.8(s)-270(i)-15.7(d)10.8(e)-.7(nt)-15.7(i)10.6().6(ed)-276(thems)-15.7(e)9.9(l).4(ve)-15.7(s)-260.8(a)-.7(s)-275.8(s).7(mo)-15.7(k)10.9(e)-.7(rs)-15.7(.)-261.9(T)-.7(he)-271.4(me)-15.7(a)8.6(n)-270.2(le)-15.7(n)9.7(g).5(th)-276(of)]TJ
0 -1.1174 TD
[(t)-15.6(h)10.9(erap)-15.6(y)-259.7(w)-.3(a)-15.6(s)-260.7(26)-15.6(.)14.4(6)]TJ
/F6 1 Tf
6.8195 0 TD
0 Tc
()Tj
/F4 1 Tf
.7027 0 TD
-.0157 Tc
[(23.1)-276(m)-.7(onth)-15.7(s)11.1(,)-272.6(g).5(iv)-15.7(e)9.7(n)-270.2(t)-15.7(h)10.8(at)-270.4(s)-15.7(o)11.1(me)-277.1(patie)-15.7(n)9.7(t).4(s)-275.8(w)-.4(ho)]TJ
-7.5222 -1.1116 TD
0 Tc
[(ac)18.5(hi)14.9(ev)19.7(ed)-320.1(co)19.7(mp)19.6(le)19.6(te)-320.3(re)19.7(gr)20.9(es)19.9(si)15.1(on)-319(of)-313.2(th)15(e)-324.8(d)0(i)15(s)0(e)19.9(a)0(s)19.9(e)-330.6(el)19.5(ec)18.5(te)19.6(d)-329.4(t)0(o)-319.1(l)0(e)19.6(a)0(v)19.7(e)]TJ
T*
-.0196 Tc
[(t)-19.6(h)-4.6(e)-188.9(L)-19.6(NG)-19.6(-I)-19.6(UD)]TJ
/F5 1 Tf
5.6503 0 TD
0 Tc
[(in)-157.8(si)20.9(tu)]TJ
/F4 1 Tf
2.5285 0 TD
[(as)-158.7(co)13.9(nt)20.7(ra)19.7(ce)18.5(pt)20.7(iv)20.7(e)-175(d)0(e)19.7(v)0(i)20.7(c)0(e)-160(a)0(n)13.9(d)-168.1(so)21(me)-160.1(pa)13.9(ti)20.6(en)19.7(ts)]TJ
-8.1788 -1.1174 TD
[(wh)14.2(o)-306.4(e)0(x)19.7(p)0(e)19.7(r)0(i)20.7(m)0(e)18.4(n)0(t)20.7(e)0(d)-297.1(r)0(e)14(l)0(a)19.5(p)0(s)21(e)-307.5(re)19.7(fu)20.9(se)14.1(d)-306.4(h)0(y)20.8(s)0(t)20.9(e)0(r)19.7(e)0(c)18.5(t)0(o)15(m)0(y)-297.2(a)0(n)19.7(d)-306.4(ch)19.7(os)21(e)-307.5(a)]TJ
0 -1.1116 TD
[(se)14.1(co)19.7(nd)-486(cy)19.7(cl)19.6(e)-497.6(o)0(f)-486(c)0(o)19.7(n)0(s)15.3(e)0(r)19.7(v)0(a)19.7(t)0(i)20.6(v)0(e)-487.2(t)0(r)20.7(e)0(a)18.5(t)0(m)13.7(e)0(n)19.7(t)-496.6(af)19.7(te)19.6(r)-496.4(r)0(e)19.7(-)0(e)19.7(v)0(a)13.9(l)0(u)20.7(a)0(t)19.6(i)0(n)20.7(g)]TJ
T*
[(ri)15(sk)21(s)-271.6(a)0(n)19.7(d)-271.8(pr)20.9(ov)20.8(id)20.7(in)20.7(g)-271.8(a)-273(ne)19.7(w)-272.7(w)0(r)20(i)0(t)20.6(t)0(e)19.6(n)-271.8(in)20.7(fo)20.9(rm)19.6(ed)-262.5(co)19.7(ns)21(en)13.9(t.)]TJ
1.0137 -1.1174 TD
[(Regarding)-301.4(treatment)-303(outcomes,)-303.7(32.7%)-296.9(of)-295.9(women)-302.5(showed)]TJ
-1.0137 -1.1116 TD
[(treatment)-423.9(failure)-419.2(\(9.3%)-412(had)-419.2(no)-411.1(regression,)-419.6(and)-419.2(23.3%)-412.1(ex-)]TJ
T*
[(perimented)-361.5(relapse\).)-361.2(A)-353.3(second)-360.1(regression)-358.6(after)-359.2(relapse)-356.7(was)]TJ
T*
[(observed)-252.8(in)-250(44.4%)-245(of)-249.8(women)-250.7(who)-246.1(underwent)-249.4(a)-249.9(second)-250.6(cycle)]TJ
0 -1.1174 TD
[(of)-583.9(conservative)-582.4(treatment.)-582.9(A)-583.7(successful)-584.2(pregnancy)-583.6(after)]TJ
0 -1.1116 TD
[(treatment)-452.7(was)-454.4(achieved)-451.3(in)-445.8(23.3%)-446.6(of)-451.4(the)-448.1(patients)-449.1(who)-447.7(at-)]TJ
T*
[(tempted)-288(to)-278.8(conceive.)]TJ
1.0137 -1.1174 TD
[(Outcomes)-289.6(and)-280.9(clinical)-289.3(factors)-286.4(are)-287.8(presented)-289.8(by)-278.7(pathology)]TJ
-1.0137 -1.1116 TD
[(diagnosis)-287.4(\(AEH)-278(and)-280.9(EEC\))-284.3(in)-278.8(Table)-285.6(1.)]TJ
/F10 1 Tf
8.9663 0 0 8.9663 59.7543 83.9622 Tm
[(Clinical)-340.5(predictive)-332.5(factors)-333.2(of)-336.7(response)-333.1(to)-330.4(treatment)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 67.5212 Tm
[(Among)-439.6(all)-436.7(23)-439.9(clinical)-439(factors)-441.9(assessed)-443.5(as)-435.1(predictive)-441.1(of)]TJ
-1.0137 -1.1116 TD
[(response)-269.9(to)-267.3(conservative)-271.3(treatment)-268.4(in)-267.3(women)-268(with)-264.7(AEH)-271.2(and)]TJ
25.5097 67.9242 TD
[(EEC,)-269.4(3)-271.8(factors)-269.1(showed)-273.4(a)-273(signicant)-272.6(association)-274.8(with)-270.5(at)-268.4(least)]TJ
0 -1.1174 TD
[(one)-321.3(treatment)-326(outcome)-322.4(at)-320.3(univariate)-325.9(analyses.)-326.5(In)-324.7(particular,)]TJ
0 -1.1116 TD
[(treatment)-349.1(failure)-355.8(was)-345(signicantly)-355.5(associated)-349.6(with)-351.1(a)-347.8(longer)]TJ
T*
[(menstrual)-393.6(cycle)-389.3(\()]TJ
/F5 1 Tf
7.3609 0 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.002\),)-386.7(infrequent)-393.7(menstrual)-393.7(bleeding)]TJ
-8.749 -1.1116 TD
[(\(two)-327.9(or)-324.7(less)-333.6(episodes)-327.7(in)-330.6(a)-324.8(9)0(0)-330.5(days)-327.9(period\))-331.5(\()]TJ
/F5 1 Tf
18.0221 0 TD
(p)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.04\),)-328(and)-332.8(a)]TJ
-19.4044 -1.1174 TD
[(diagnosis)-391.1(of)-388.1(EEC)-386.9(instead)-390.2(of)-388.1(AEH)-392.1(\()]TJ
/F5 1 Tf
15.0674 0 TD
(p)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.008\).)-392.5(Among)-387.8(the)]TJ
-16.4497 -1.1116 TD
-.0203 Tc
[(se)-5.3(condary)-286.3(outcom)-5.3(e).5(s,)-288.7(infreq)]TJ
10.6439 0 TD
-.0215 Tc
[(u)-5.3(e)-.7(nt)-287.7(me)-6.5(ns)-5.1(tru)-5.3(a)-.7(l)-287.7(b).4(l)-5.4(eed)-5.3(ing)-287.5(\()]TJ
/F5 1 Tf
10.068 0 TD
0 Tc
(p)Tj
/F6 1 Tf
.6451 0 TD
(=)Tj
/F4 1 Tf
.6969 0 TD
-.0171 Tc
[(0.0)4.9(4)4.8(\),)]TJ
-22.0539 -1.1116 TD
0 Tc
[(and)-419.2(a)-417(diagnosis)-414.1(of)-416.9(EEC)-421.4(instead)-413.3(of)-422.6(AEH)-415.2(\()]TJ
/F5 1 Tf
17.9645 0 TD
(p)Tj
/F6 1 Tf
.6624 0 TD
(<)Tj
/F4 1 Tf
.72 0 TD
[(0.001\))-417.8(were)]TJ
-19.3469 -1.1174 TD
[(signicant)9.7(ly)-451.6(associated)-447.5(with)-443.3(no)-451.5(regression)-445(of)-445.7(the)-448.1(disease,)]TJ
0 -1.1116 TD
[(while)-520.4(relapse)-523.7(of)-520.5(the)-523(disease)-523.6(was)-523.5(signicant)9.7(ly)-520.7(associated)]TJ
T*
[(with)-270.5(a)-278.7(longer)-272.8(menstrual)-272.7(cycle)-274.1(\()]TJ
/F5 1 Tf
12.7347 0 TD
(p)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.007\).)-271.5(No)-273.8(clinical)-272(factor)]TJ
-14.117 -1.1174 TD
[(was)-293.1(signicantly)-292.2(associated)-292(with)-299.3(successful)-290.5(pregnancy)-295.6(after)]TJ
0 -1.1116 TD
[(treatment)8(.)]TJ
1.0137 -1.1116 TD
[(All)-303.9(univariate)-308.6(analyses)-311.6(assessing)-305.3(association)-309.3(between)-311.7(the)]TJ
-1.0137 -1.1116 TD
[(clinical)-283.5(factor)-285.5(and)-280.9(each)-278.6(outcome)-282.1(are)-287.8(reported)-281.9(in)-278.8(Table)-285.6(2.)]TJ
1.0137 -1.1174 TD
[(At)-371.8(the)-379(multivariate)-375.7(logistic)-378.9(regression)-375.9(analysis,)-383.1(a)-370.9(longer)]TJ
-1.0137 -1.1116 TD
[(menstrual)-336.1(cycle)-331.7(was)-333.5(signicantly)-338.2(associated)-332.3(with)-333.8(treatment)]TJ
T*
[(failure)-211.8(\(odds)-212.6(ratio)-208.5([OR])]TJ
/F6 1 Tf
9.5323 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(2.10;)-209.6(95%)-211.7(condence)-216(interval)-207.3([CI],)]TJ
-10.2523 -1.1174 TD
(1.034.29;)Tj
/F5 1 Tf
4.6481 0 TD
(p)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.042\),)-369.4(while)-364.9(a)-365.1(diagnosis)-373.8(of)-365(EEC)-363.8(instead)-373(of)]TJ
-6.0304 -1.1116 TD
[(AEH)-202.1(was)-201(not)-199.3(associated)-205.6(to)-203.9(treatment)-205.1(failure)-200.3(\(OR)]TJ
/F6 1 Tf
19.5081 0 TD
(=)Tj
/F4 1 Tf
.7142 0 TD
[(4.54;)-203.8(95%)]TJ
-20.2223 -1.1116 TD
[(CI,)-294.6(0.2484.4;)]TJ
/F5 1 Tf
6.1226 0 TD
(p)Tj
/F6 1 Tf
.6624 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(0.3\).)-298.1(Since)-295.8(infrequent)-295.8(menstrual)-301.5(bleeding)]TJ
-7.5049 -1.1174 TD
[(perfectly)-220.9(predicted)-221(the)-217.7(outcome,)-222.2(the)-217.7(variable)-219.9(was)-218.3(dropped)-221.9(by)]TJ
0 -1.1116 TD
[(the)-281.1(model)-278.7(\(Table)-286.7(3\).)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 310.8472 462.0471 Tm
(Discussion)Tj
/F10 1 Tf
0 -1.8336 TD
[(Main)-329.9(ndings)-336.1(and)-335.7(interpretation)]TJ
/F4 1 Tf
9.843 0 0 9.843 320.8251 429.1653 Tm
[(Our)-384.3(study)-385.6(assessed)-385.9(the)-384.7(role)-385.8(of)-382.3(23)-388.1(clinical)-387.2(factors)-390(in)-382.5(the)]TJ
-1.0137 -1.1116 TD
[(prediction)-278.6(of)-278.6(the)-281.1(response)-281.4(to)-278.8(treatment)-285.7(in)-278.8(women)-279.5(with)-282(AEH)]TJ
T*
[(and)-286.7(EEC)-294.7(undergoing)-288.7(conservative)-300.1(management.)-292.4(Three)-291.2(clin-)]TJ
0 -1.1174 TD
[(ical)-277.7(risk)-280.8(factors,)-284(\(1\))-279.7(longer)-278.6(menstrual)-284.2(cycle,)-283.3(\(2\))-279.7(diagnosis)-281.7(of)]TJ
0 -1.1116 TD
[(EEC)-404.1(instead)-401.8(of)-399.6(AEH,)-401.3(and)-401.9(\(3\))-406.4(infrequent)-399.4(menstrual)-405.2(bleed-)]TJ
T*
[(ing,)-404.3(were)-405(signicantly)-407.4(associated)-407.2(with)-403(a)-405.4(treatment)-406.7(failure.)]TJ
0 -1.1174 TD
[(Moreover,)-412.8(a)-411.2(longer)-411(menstrual)-416.7(cycle)-412.3(was)-414.1(also)-408.7(signicantly)]TJ
0 -1.1116 TD
[(associated)-222.9(with)-224.4(relapse)-224.2(of)-221(the)-223.5(disease,)-221.7(whereas)-230.7(a)-221.1(diagnosis)-224.1(of)]TJ
T*
[(EEC)-214.1(instead)-223.2(of)-215.3(AEH)-219.3(and)-217.6(infrequent)-215.1(menstrual)-220.9(bleeding)-218.7(were)]TJ
0 -1.1174 TD
[(also)-258.9(signicantly)-257.6(associated)-263.2(with)-259(no)-255.6(regression.)-264.1(However,)-262.9(at)]TJ
0 -1.1116 TD
[(the)-281.1(multivariate)-283.5(analyses,)-280.4(only)-281(a)-278.7(longer)-278.6(menstrual)-284.2(cycle)-279.8(and)]TJ
T*
[(infrequent)-387.9(menstrual)-387.9(bleeding)-385.8(signicantly)-390.1(predicted)-388(treat-)]TJ
T*
[(ment)-277.6(failur)-8(e.)]TJ
1.0137 -1.1174 TD
[(Our)-309.4(results)-319.7(are)-316.6(in)-313.4(agreement)-315.4(with)-316.6(prior)-310.8(published)-316.4(studies)]TJ
-1.0137 -1.1116 TD
[(in)-353.7(which)-359(longer)-359.2(menstrual)-364.8(cycles)-355.6(and)-361.6(infrequent)-359.1(menstrual)]TJ
T*
[(bleeding)-374.3(are)-380(linked)-376.6(to)-370.9(chronic)-378.8(anovulation)-377.7(or)-376.5(ovarian)-378.8(dys-)]TJ
0 -1.1174 TD
[(function,)-445.6(which)-439.6(have)-444.5(been)-444.5(associated)-453.3(with)-443.3(lower)-445.4(rates)-445.5(of)]TJ
0 -1.1116 TD
[(response)-264.1(of)-267.1(AEH)-265.4(and/or)-267.1(EEC)-265.9(to)-261.5(conservative)-271.3(treatment.)]TJ
7.3823 0 0 6.5614 533.3101 247.2377 Tm
(36,39)Tj
9.843 0 0 9.843 310.8472 231.9306 Tm
[(The)-357(reason)-360(may)-362.8(be)-360.5(found)-356.8(in)-359.4(the)-355.9(pathogenesis)-367.9(of)-353.5(AEH)-363.3(and)]TJ
0 -1.1174 TD
[(EEC,)-188.7(as)-187.5(a)-192.3(consequence)-196.3(of)-186.5(a)-186.6(continuous)-190.8(estrogenic)-193.1(action)-193.5(over)]TJ
0 -1.1116 TD
[(the)-309.9(endometrium)-310.9(unopposed)-316.2(by)-307.5(progesterone.)]TJ
7.3823 0 0 6.5614 493.7952 214.3559 Tm
(40,41)Tj
9.843 0 0 9.843 513.4676 209.9905 Tm
[(Such)-310.7(im-)]TJ
-20.5852 -1.1116 TD
[(balance)-312(is)-307.4(the)-304.1(basis)-311.7(of)-307.4(the)-309.9(use)-309.5(of)-307.4(progestins)-305.8(as)-308.4(conservative)]TJ
0 -1.1174 TD
[(treatment)-360.6(for)-360.3(these)-364.9(lesions.)-357.8(Other)-364.7(conditions)-363.7(such)-356.7(as)-360.3(infre-)]TJ
0 -1.1116 TD
[(quent)-461.8(menstrual)-462.8(bleeding)-460.7(or)-457.2(long)-465.3(menstrual)-462.8(cycles)-459.3(might)]TJ
T*
[(cause)-412(an)-406.5(excess)-412.9(of)-405.3(endogenous)-410.6(estrogens)-409.4(that)-409(antagonizes)]TJ
T*
[(the)-229.2(progestin)-235.7(therapeutic)-236(action.)-231.5(Our)-228.8(nding,)-234.6(if)-226.9(conrmed)-236.8(on)]TJ
0 -1.1174 TD
[(other)-352.4(larger)-348.8(cohorts,)-352(will)-351.2(help)-351.3(counseling)-353.2(patients,)-354.6(promot-)]TJ
0 -1.1116 TD
[(ing)-326(a)-324.8(closer)-325.6(follow-up)-327.8(and/or)-330.4(a)-324.8(different)-329.2(treatment)-331.8(protocol)]TJ
T*
[(\(e.g.,)-239.4(association)-240.2(of)-238.3(progestins,)-240.1(higher)-244(progestin)-235.7(dose,)-239.2(higher)]TJ
0 -1.1174 TD
[(treatment)-475.8(length\))-475.6(for)-475.5(patients)-477.9(with)-477.8(long)-476.8(menstrual)-474.3(cycles)]TJ
0 -1.1116 TD
[(and/or)-278.6(infrequent)-284.2(menstrual)-284.2(bleeding.)]TJ
1.0137 -1.1116 TD
[(Regarding)-566.3(other)-571.2(clinical)-571.5(factors,)-572(which)-572.1(did)-567.9(not)-567.9(show)]TJ
-1.0137 -1.1174 TD
[(predictive)-487.2(value)-491.8(in)-480.4(our)-487.1(study,)-486.9(results)-486.8(of)-486(previous)-487.9(studies)]TJ
0 -1.1116 TD
[(are)-362.7(conicting.)-362.6(In)-359.3(particular,)-363.8(we)-367.1(found)-356.8(no)-359.3(predictive)-366.2(value)]TJ
T*
[(for)-538.9(having)-543.6(personal)-540.9(history)-537.6(of)-543.6(PCOS,)-539.3(sterility/infertility,)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(PREDICTIVE)-341.6(FACTORS)-336.8(IN)-335.1(CONSERVATIVELY)-339.1(TREATED)-338(AEH)-332.3(AND)-337.2(EEC)-19757.7(3)]TJ
ET
endstream
endobj
47 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 62.022 231.9873 Tm
0 0 0 rg
0 Tc
0 Tw
[(previous)-246(pregnancies,)-250.5(or)-244.1(obesity,)-248.5(which)-243.8(is)-249.8(in)-244.2(agreement)-246.3(with)]TJ
0 -1.1116 TD
[(studies)-394.6(by)-393.9(other)-392.7(authors.)]TJ
7.3823 0 0 6.5614 162.5952 225.411 Tm
[(23,3)-8.6(6,42)]TJ
9.843 0 0 9.843 192.359 221.0456 Tm
[(However,)-395.3(other)-392.7(studies)-394.6(re-)]TJ
-13.2416 -1.1174 TD
[(ported)-295.9(person)-7.5(al)-297.2(history)-295.7(of)-295.9(PCOS)-299.7(to)-296.1(be)-297.1(both)-298.3(a)-296(risk)-298(factor)-297(for)]TJ
0 -1.1116 TD
[(endometrial)-310.9(cancer)-310.7(\(three)-314.3(times)-307.5(increased)-308.2(risk\))]TJ
7.3823 0 0 6.5614 250.1291 203.4708 Tm
(43)Tj
9.843 0 0 9.843 260.5605 199.1054 Tm
[(and)-304(a)-307.5(pre-)]TJ
-20.1705 -1.1116 TD
[(dictive)-327.2(factor)-331.5(of)-324.7(poor)-326.9(response)-327.5(to)-324.9(conservative)-328.9(treatment)-331.8(in)]TJ
T*
[(AEH)-409.4(and)-413.4(EEC.)]TJ
7.3823 0 0 6.5614 125.6315 181.5874 Tm
(33)Tj
9.843 0 0 9.843 137.0267 177.222 Tm
[(In)-411.1(fact,)-413.4(PCOS)-409.2(has)-407.4(been)-409.9(associated)-413(with)]TJ
-7.6201 -1.1174 TD
[(metabolic)-314.5(features)-317.4(that)-311.1(increase)-312.9(the)-309.9(risk)-309.6(of)-313.2(cancer)-316.5(\(e.g.,)-308.5(hy-)]TJ
0 -1.1116 TD
[(perinsulinism,)-625(insulin)-624.2(resistance,)-629.5(hyperandrogenism,)-624.7(and)]TJ
T*
[(hyperglycemia\),)-370.5(it)-371.1(is)-365(unclear)-374.2(if)-365.2(the)-367.5(increased)-371.6(risk)-367.2(of)-365(endo-)]TJ
0 -1.1174 TD
[(metrial)-276.6(cancer)-276.2(may)-270.6(be)-274.1(due)-275.2(to)-267.3(PCOS)-276.7(itself)-272.9(or)-272.9(to)-273(other)-271.7(related)]TJ
0 -1.1116 TD
[(risk)-269.2(factors.)]TJ
7.3823 0 0 6.5614 108.737 126.7653 Tm
(33)Tj
9.843 0 0 9.843 118.7716 122.3999 Tm
[(An)-268(explanation)-275.2(of)-267.1(a)-267.2(PCOS-specic)-277.2(risk)-269.2(might)]TJ
-5.7655 -1.1116 TD
[(be)-400.8(that)-397.5(both)-396.2(serum)-399.3(estrogens)-397.9(and)-401.9(androgen)-397(levels)-400.7(are)-397.3(sig-)]TJ
0 -1.1174 TD
[(nicantly)-242.9(elevated)-244.1(in)-244.2(patients)-241.7(with)-241.7(PCOS.)-245.6(Thus,)-239.2(endogenous)]TJ
0 -1.1116 TD
[(estrogen)-293.3(levels)-297(may)-293.7(be)-291.3(increased)-296.7(also)-293.5(by)-290.2(peripheral)-296.9(conver-)]TJ
T*
[(sion)-309.6(of)-307.4(androgens)-305.8(to)-307.6(estrogens.)]TJ
7.3823 0 0 6.5614 186.5763 82.9417 Tm
(33)Tj
9.843 0 0 9.843 197.0078 78.5763 Tm
[(In)-307.4(addition,)-307.5(other)-312(ndings)]TJ
-13.7139 -1.1116 TD
[(seem)-232.4(also)-230.1(to)-232.7(indicate)-231.6(a)-232.6(progestin)-230(resistance)-240.1(at)-228.1(the)-235(level)-232.7(of)-226.8(the)]TJ
0 -1.1174 TD
[(endometrium)-454.9(of)-445.7(women)-452.3(with)-449(PCOS)-449.5(as)-446.7(a)-445.8(result)-451.3(of)-451.4(an)-446.9(in-)]TJ
25.504 17.8148 TD
[(ammatory)-642.4(microenvironment)-640.2(induced)-638(by)-635.8(insulin)-635.7(resis-)]TJ
0 -1.1116 TD
[(tance)-245.3(associated)-245.9(with)-247.4(PCOS.)]TJ
7.3823 0 0 6.5614 426.2172 225.411 Tm
[(33,3)-8.6(4,37,444)-8.7(7)]TJ
9.843 0 0 9.843 474.8597 221.0456 Tm
[(However,)-245.6(given)-242.9(the)]TJ
-16.4382 -1.1174 TD
[(conicting)-457.1(ndings,)-448.7(the)-453.8(predictive)-452.6(value)-457.2(of)-445.7(PCOS)-455.3(is)-451.4(still)]TJ
0 -1.1116 TD
(uncertain.)Tj
1.0137 -1.1116 TD
[(Regarding)-307.1(infertility)-302(and)-298.2(previous)-303.6(pregnancies,)-302.3(a)-301.8(system-)]TJ
-1.0137 -1.1116 TD
[(atic)-191.3(review)-188.4(and)-188.8(meta-analysis)-193(found)-184(that)-190.1(they)-184.2(were)-191.9(associated)]TJ
0 -1.1174 TD
[(with)-506.6(regression)-508.4(of)-509(AEH)-501.6(and)-505.6(EEC.)]TJ
7.3823 0 0 6.5614 459.7227 170.5889 Tm
(23)Tj
9.843 0 0 9.843 472.0818 166.2236 Tm
[(Such)-506.5(results)-504(are)-506.7(in)]TJ
-16.156 -1.1116 TD
[(contrast)-379.8(with)-374.2(our)-371.9(ndings.)-379.5(However,)-372.3(those)-375.2(authors)-377.4(did)-372.1(not)]TJ
T*
[(nd)-319.9(a)-319(clear)-320.1(pathophysiological)-329.1(explanation)-321.3(for)-314.3(such)-322.2(associ-)]TJ
0 -1.1174 TD
[(ations)-7.8(,)-199.3(concluding)-203.7(that)-195.9(there)-203.8(is)-203.7(need)-202.6(of)-198(conrmation)-205.8(by)-198(larger)]TJ
0 -1.1116 TD
[(studie)-7.8(s.)]TJ
1.0137 -1.1116 TD
[(Regarding)-405(obesity,)-404(we)-401.7(found)-397.1(no)-399.6(predictive)-406.5(of)-399.6(treatment)]TJ
-1.0137 -1.1174 TD
[(failur)-8(e)-411.2(value,)-408.8(in)-411.3(contrast)-414.4(with)-414.5(results)-411.9(of)-411.1(other)-409.9(studie)-7.8(s)-409.8(that)]TJ
0 -1.1116 TD
[(report)-7.8(ed)-412.3(poor)-413.3(response)-413.9(to)-417(conservative)-415.3(treatment)-418.2(in)-417(obese)]TJ
T*
(patients.)Tj
7.3823 0 0 6.5614 346.3369 82.9417 Tm
(36,37,39,48,49)Tj
9.843 0 0 9.843 395.3763 78.5763 Tm
[(The)-472.2(possible)-476.4(effect)-476.7(of)-474.5(obesity)-475.5(on)-474.5(the)]TJ
-8.3631 -1.1116 TD
[(respon)-7.5(se)-285.4(to)-284.6(proges)-7.6(tins)-286.7(might)-283.5(lie)-292.7(in)-284.6(an)-285.6(excess)-291.9(of)-290.1(endogenous)]TJ
0 -1.1174 TD
[(estrogens,)-234.3(as)-227.8(a)-226.9(consequence)-236.6(of)-226.8(chronic)-229(hyperinsulinemia)-235.8(and)]TJ
ET
62.022 709.512 490.167 .22681 re
f
62.022 350.249 490.167 .22678 re
f
62.022 680.882 490.167 .22681 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 124.9511 725.1588 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(1.)Tj
/F9 1 Tf
1.2496 0 TD
[(Pretreatment)-330.4(Clinical)-338.5(Factors)-334.5(and)-332(Primary)-335.8(and)-332(Secondary)-331.7(Outcomes,)]TJ
5.0675 -1.0135 TD
[(Overall,)-333.2(and)-332(by)-335.8(Histological)-334.6(Diagnosis)]TJ
/F5 1 Tf
-15.7093 -2.8562 TD
(Variables)Tj
24.3183 1.0135 TD
[(All)-332.7(women)]TJ
.645 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.6622 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
(43\))Tj
6.4956 1.0135 TD
[(AEH)-334.4(diagnosis)]TJ
1.5318 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7141 0 TD
(37\))Tj
7.3018 1.0135 TD
[(EEC)-334.5(diagnosis)]TJ
1.7564 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7141 0 TD
(6\))Tj
/F4 1 Tf
-47.197 -1.8946 TD
[(Pretreatment)-340.6(clinical)-334.6(factors)]TJ
1.002 -1.0135 TD
[(Mean)-335.4(age)-333.6(at)-337.3(the)-332.6(time)-334.9(of)-330.2(diagnosis,)-335.9(SD)-7598.2(36.0)-328.8(\(5.7\))-5748.6(36.1)-328.8(\(5.9\))-6526(35.5)-334.6(\(4.5\))]TJ
0 -1.0077 TD
[(Mean)-335.4(BMI)-333(in)-336.2(kg/m)]TJ
7.3837 0 0 6.5625 150.7464 652.8754 Tm
(2)Tj
9.845 0 0 9.845 154.4314 648.5101 Tm
[(,)-331.6(S)0(D)-13253(28.5)-328.8(\(7.6\))-5748.6(27.9)-328.8(\(7.6\))-6526(32.4)-334.6(\(7.1\))]TJ
-8.3844 -1.0135 TD
[(Cigarette)-336.4(smoke,)-333(%)-16563.6(16.7)-8241.1(16.7)-8529(16.7)]TJ
T*
[(Hypertension,)-335.3(%)-17801.6(14.0)-8241.1(13.5)-8529(16.7)]TJ
T*
[(Mean)-335.4(age)-333.6(at)-337.3(menarche)-336.2(in)-330.4(years,)-338.7(SD)-8761.4(11.6)-328.8(\(1.2\))-5748.6(11.6)-328.8(\(1.2\))-6526(11.3)-334.6(\(1.4\))]TJ
0 -1.0077 TD
[(Mean)-335.4(menstrual)-335.1(cycle)-336.9(length)-335.7(in)-330.4(days,)-336.6(SD)-6481(28.8)-328.8(\(3.5\))-5748.6(28.2)-328.8(\(2.6\))-6526(32.3)-334.6(\(5.1\))]TJ
0 -1.0135 TD
[(Mean)-335.4(menstrual)-335.1(phase)-335.4(length)-335.7(in)-330.4(days,)-336.6(SD)-6573.1(4.6)-333.6(\(1.3\))-6243.8(4.4)-333.6(\(1.3\))-7027(5.4)-333.6(\(1.1\))]TJ
T*
[(Heavy)-336.3(menstrual)-335.1(bleeding)-333.1(with)-333.4(or)-336(without)]TJ
.9847 -1.0135 TD
[(prolonged)-332.7(menstrual)-335.1(bleeding,)-336.5(%)]TJ
23.6273 1.0135 TD
[(33.3)-8241.1(30.6)-8529(50.0)]TJ
-24.612 -2.0213 TD
[(Infrequent)-334.9(menstrual)-335.1(bleeding,)-336.5(%)-11438.5(4.8)-8741.1(2.8)-8528(16.7)]TJ
0 -1.0135 TD
[(Frequent)-332.7(menstrual)-335.1(bleeding,)-336.5(%)-12054.6(7.1)-8741.1(5.6)-8528(16.7)]TJ
T*
[(Irregular)-333.9(nonmenstrual)-338(bleeding,)-336.5(%)-10603.5(9.5)-8240.1(11.1)-9030(0.0)]TJ
T*
[(Vaginal)-332.9(discharge,)-338.3(%)-16344.7(4.8)-8741.1(5.6)-9029(0.0)]TJ
0 -1.0077 TD
[(Previous)-331.4(pregnancies,)-341.4(%)-14571.1(39.5)-8241.1(43.2)-8529(16.7)]TJ
0 -1.0135 TD
[(PCOS)-333.7(diagnosis,)-335.9(%)-16592.4(16.7)-8241.1(16.7)-8529(16.7)]TJ
T*
[(Sterility)-333.3(or)-336(infertility,)-333.2(%)-15158.5(7.1)-8741.1(5.6)-8528(16.7)]TJ
0 -1.0077 TD
[(Family)-330.9(history)-335.3(of)-336(endometrial)-338.6(cancer,)-336.5(%)-8478.6(9.3)-8240.1(10.8)-9030(0.0)]TJ
0 -1.0135 TD
[(Family)-330.9(history)-335.3(of)-336(leukemia,)-333(%)-12054.6(23.3)-8241.1(18.9)-8529(50.0)]TJ
T*
[(Family)-330.9(history)-335.3(of)-336(thyroid)-335.5(diseases,)-336.9(%)-9227.2(27.9)-8241.1(29.7)-8529(16.7)]TJ
T*
[(Previous)-331.4(nonendometrial)-341.5(cancer)-333.1(diagnosis,)-335.9(%)-5990.9(15.4)-8241.1(17.4)-9030(0.0)]TJ
0 -1.0077 TD
[(Use)-333(of)-336(oral)-333.5(contraceptives,)-340.2(%)-12446.2(29.3)-8241.1(31.4)-8529(16.7)]TJ
0 -1.0135 TD
[(Use)-333(of)-336(hormone)-331.7(administration)-340.5(for)-331.2(assisted)]TJ
.9847 -1.0135 TD
[(reproductive)-332.5(technology,)-338.4(%)]TJ
23.6273 1.0135 TD
[(26.2)-8241.1(27.8)-8529(16.7)]TJ
-24.612 -2.027 TD
[(Pelvic)-336.7(pain,)-331.2(%)-18625.1(16.7)-8241.1(19.4)-9030(0.0)]TJ
0 -1.0077 TD
[(Mean)-335.4(length)-335.7(of)-330.2(therapy)-337.7(in)-330.4(months,)-333(SD)-7356.3(26.6)-334.6(\(23.1\))-5242.8(26.5)-334.6(\(23.4\))-6026(27.5)-334.6(\(23.5\))]TJ
-1.002 -1.3187 TD
[(Post-treatment)-341.4(outcomes)]TJ
7.3837 0 0 6.5625 160.7811 410.74 Tm
(a)Tj
9.845 0 0 9.845 71.8866 396.4534 Tm
[(Regression,)-333.2(%)-18751.8(90.7)-7745.8(100)-9274.2(33.3)]TJ
0 -1.0135 TD
[(AEH/EEC)-335.7(relapse,)-336.3(%)]TJ
7.3837 0 0 6.5625 158.7401 390.8408 Tm
(b)Tj
9.845 0 0 9.845 314.192 386.4755 Tm
[(23.3)-8241.1(21.6)-8529(50.0)]TJ
-24.612 -1.0135 TD
[(Treatment)-337.6(failure)-332.1(\(No)-337.8(regression/relapse\),)-339(%*)-5813.3(32.6)-8241.1(21.6)-8529(83.3)]TJ
T*
[(Postrelapse)-336.7(regression,)-337.9(%)]TJ
7.3837 0 0 6.5625 174.5007 370.9417 Tm
(c)Tj
9.845 0 0 9.845 314.192 366.5196 Tm
[(44.4)-8241.1(50.0)-9030(0.0)]TJ
-24.612 -1.0077 TD
[(Successful)-335.5(pregnancies)-338.1(after)-335.7(treatment,)-340(%)-7476.6(23.3)-8241.1(27.0)-9030(0.0)]TJ
8.7511 0 0 8.7511 70.0157 338.4566 Tm
[(Given)-268.4(the)-275(very)-267.2(few)-277.1(women)-267.3(with)-273.6(a)-272.1(diagnosis)-270(of)-268.3(EEC,)-272.4(the)-275(analyses)-268.3(were)-277.1(severely)-268.5(underpowered)-274(to)-268.5(detect)-279.1(any)-269.8(signicant)-270.2(difference)-272.5(in)-268.5(the)]TJ
-.9134 -1.0236 TD
[(distribution)-423.7(of)-423.8(the)-417.5(recorded)-425.4(exposures)-421.3(between)-430.4(the)-417.5(two)-425.1(groups.)-420.2(The)-427.9(only)-421.6(comparison)-418(achieving)-424.6(statistical)-426.9(signicance)-421.6(\()]TJ
/F5 1 Tf
50.5701 0 TD
(p)Tj
/F6 1 Tf
.6673 0 TD
(<)Tj
/F4 1 Tf
.7191 0 TD
[(0.05\))-424.1(was)]TJ
-51.9565 -1.0301 TD
[(identied)-331.3(with)-338.4(the)-333.3()60.9(*)58.2()-334.3(\()]TJ
/F5 1 Tf
10.3459 0 TD
(p)Tj
/F6 1 Tf
.6673 0 TD
(=)Tj
/F4 1 Tf
.7191 0 TD
[(0.02\).)-329.6(All)-339.6(other)]TJ
/F5 1 Tf
6.6727 0 TD
(p)Tj
/F4 1 Tf
.8357 0 TD
[(that)-330.9(were)-335.4(not)-332.1(reported)-332.2(were)]TJ
/F6 1 Tf
11.687 0 TD
(>)Tj
/F4 1 Tf
.5507 0 TD
(0.05.)Tj
6.5633 0 0 5.8334 70.0157 315.4393 Tm
(a)Tj
8.7511 0 0 8.7511 72.9637 311.5275 Tm
[(The)-317.7(raw)-315.9(number)-320.7(of)-313.7(women)-319.1(experiencing)-317.2(at)-321.5(least)-322.8(one)-315.1(outcome)-320.9(among)-316.8(those)-316.4(reported)-319.3(is:)-316.3(regression:)]TJ
/F5 1 Tf
40.8461 0 TD
(n)Tj
/F6 1 Tf
.6673 0 TD
(=)Tj
/F4 1 Tf
.7191 0 TD
[(39;)-319.2(relapse:)]TJ
/F5 1 Tf
5.0402 0 TD
(n)Tj
/F6 1 Tf
.6673 0 TD
(=)Tj
/F4 1 Tf
.7191 0 TD
[(10;)-312.7(postrelapse)]TJ
-49.9093 -1.0236 TD
(regression:)Tj
/F5 1 Tf
4.7292 0 TD
(n)Tj
/F6 1 Tf
.6608 0 TD
(=)Tj
/F4 1 Tf
.7191 0 TD
[(4;)-333.3(successful)-334.2(pregnancy)-335(after)-335.7(treatment:)]TJ
/F5 1 Tf
16.6559 0 TD
(n)Tj
/F6 1 Tf
.6673 0 TD
(=)Tj
/F4 1 Tf
.7191 0 TD
(10.)Tj
6.5633 0 0 5.8334 70.0157 297.5243 Tm
(b)Tj
8.7511 0 0 8.7511 73.3039 293.6125 Tm
[(Four)-330.6(missing)-333.5(values.)]TJ
6.5633 0 0 5.8334 70.0157 288.5102 Tm
(c)Tj
/F5 1 Tf
8.7511 0 0 8.7511 72.9637 284.6551 Tm
(n)Tj
/F6 1 Tf
.6608 0 TD
(=)Tj
/F4 1 Tf
.7191 0 TD
[(10)-334.5(women)-332.1(with)-332(relapse.)]TJ
-1.7168 -1.0236 TD
[(BMI,)-301.9(body)-299.8(mass)-301.8(index;)-296.1(SD,)-306.9(standard)-299.7(deviation;)-303.1(PCOS,)-300.4(polycystic)-302.7(ovary)-298.4(syndrome;)-301.4(AEH,)-304.3(atypical)-301.4(endometrial)-300.5(hyperplasia;)-300.2(EEC,)-304.8(early)]TJ
-.9134 -1.0236 TD
[(endometrial)-332.9(cancer.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(4)Tj
46.2711 0 TD
[(RAFFONE)-336.8(ET)-338.7(AL.)]TJ
ET
endstream
endobj
52 0 obj
<>stream
0 0 0 rg
/GS1 gs
131.414 56.58 .28346 699.704 re
f
460.8 56.58 .22675 699.704 re
f
180 56.58 .28346 699.704 re
f
BT
/F9 1 Tf
0 9.845 -9.845 -0 126.0283 135.8362 Tm
0 Tc
0 Tw
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(2.)Tj
/F9 1 Tf
1.2496 0 TD
[(Pretreatment)-336.1(Clinical)-332.7(Factors)-334.5(and)-337.8(Univariate)-334.2(Analyses)-331.7(Evaluating)-335.4(Their)-335.7(Relationship)-338.7(with)-334.7(Each)-334.4(Outcome)]TJ
/F5 1 Tf
-12.3002 -4.8775 TD
[(Pretreatment)-340(clinical)-333.4(factors)]TJ
20.6444 1.0135 TD
(Overall)Tj
.0058 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
(43\))Tj
3.553 2.027 TD
(Treatment)Tj
.7198 -1.0135 TD
(failure)Tj
-.19 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7141 0 TD
(14\))Tj
/F4 1 Tf
3.9907 0 TD
(p)Tj
/F5 1 Tf
.501 0 TD
(*)Tj
2.4531 1.0135 TD
(Regression)Tj
.6968 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
(39\))Tj
/F4 1 Tf
4.2613 0 TD
(p)Tj
/F5 1 Tf
.501 0 TD
(*)Tj
4.3707 2.027 TD
(No)Tj
-1.526 -1.0135 TD
(regression)Tj
.8292 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
(4\))Tj
/F4 1 Tf
4.0137 0 TD
(p)Tj
/F5 1 Tf
.501 0 TD
(*)Tj
3.363 1.0135 TD
(Relapse)Tj
.0633 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7141 0 TD
(10\))Tj
/F4 1 Tf
3.9907 0 TD
(p)Tj
/F5 1 Tf
.501 0 TD
(*)Tj
2.505 3.0405 TD
(Pregnancy)Tj
1.2266 -1.0135 TD
(after)Tj
-.979 -1.0135 TD
(treatment)Tj
.3973 -1.0135 TD
(\()Tj
/F4 1 Tf
.334 0 TD
(n)Tj
/F6 1 Tf
.668 0 TD
(=)Tj
/F5 1 Tf
.7198 0 TD
(10\))Tj
/F4 1 Tf
3.3572 0 TD
(p)Tj
/F5 1 Tf
.501 0 TD
(*)Tj
/F4 1 Tf
-70.571 -1.8946 TD
[(Mean)-335.4(BMI)-333(in)-336.2(kg/m)]TJ
0 7.3837 -6.5625 -0 188.3338 135.4393 Tm
(2)Tj
0 9.845 -9.845 -0 192.6992 139.1244 Tm
[(,)-331.6(S)0(D)-9941.9(28.5)-334.6(\(7.6\))-1804(30.6)-334.6(\(8.4\))-5357(30.4)-334.6(\(9.2\))-5909.8(28.3)-334.6(\(7.5\))-5909.8(30.7)-328.8(\(8.7\))-5362.8(30.0)-334.6(\(9.6\))]TJ
-8.3844 -1.0135 TD
[(Cigarette)-336.4(smoke,)-333(%)-13252.4(16.7)-4555.6(7.2)-27928.5(0.0)-7860(20.0)]TJ
T*
[(Hypertension,)-335.3(%)-14490.5(14.0)-4555.6(7.1)-7606.6(25.0)-8413.8(12.8)-8408.1(0.0)-7860(10.0)]TJ
0 -1.0077 TD
[(Mean)-335.4(age)-333.6(at)-337.3(menarche)-336.2(in)-330.4(years,)-338.7(SD)-5450.2(11.6)-334.6(\(1.2\))-1804(11.8)-334.6(\(1.6\))-5357(11.8)-334.6(\(0.9\))-5909.8(11.6)-334.6(\(1.2\))-5909.8(11.8)-328.8(\(1.7\))-5362.8(11.9)-334.6(\(1.2\))]TJ
0 -1.0135 TD
[(Mean)-335.4(menstrual)-335.1(cycle)-336.9(length)-335.7(in)-330.4(days,)-336.6(SD)-3169.8(28.8)-334.6(\(3.5\))-1804(31.0)-334.6(\(3.9\))-1550.6(0.002)-1556.4(28.5)-334.6(\(3.3\))-5909.8(31.5)-334.6(\(4.0\))-5909.8(30.8)-328.8(\(4.0\))-1556.4(0.007)-1556.4(28.1)-334.6(\(0.8\))]TJ
T*
[(Mean)-335.4(menstrual)-335.1(phase)-335.4(length)-335.7(in)-330.4(days,)-336.6(SD)-3262(4.6)-333.6(\(1.3\))-2305(4.6)-333.6(\(1.3\))-5858(4.5)-333.6(\(1.3\))-6410.8(4.0)-333.6(\(1.3\))-6410.8(4.4)-333.6(\(1.3\))-5858(4.3)-333.6(\(1.0\))]TJ
T*
[(Heavy)-336.3(menstrual)-335.1(bleeding)-333.1(with)-339.1(or)-330.2(without)]TJ
.9905 -1.0077 TD
[(prolonged)-332.7(menstrual)-340.8(bleeding,)-330.7(%)]TJ
20.3104 1.0077 TD
[(33.3)-4054.6(35.7)-7607.6(34.2)-8413.8(25.0)-7907.1(40.0)-7861(20.0)]TJ
-21.3008 -2.0212 TD
[(Infrequent)-334.9(menstrual)-335.1(bleeding,)-336.5(%)-8127.3(4.8)-4053.6(14.3)-2678.3(0.04)-3680.3(2.6)-3230.1(0.04)-3432.7(25.0)-2977.7(0.04)-3179.3(10.0)-7861(10.0)]TJ
0 -1.0135 TD
[(Frequent)-332.7(menstrual)-340.8(bleeding,)-330.7(%)-8743.5(7.1)-4554.6(0.0)-8107.6(7.9)-8908.1(0.0)-8412.8(0.0)-8355.2(0.0)]TJ
0 -1.0077 TD
[(Irregular)-333.9(nonmenstrual)-338(bleeding,)-336.5(%)-7292.3(9.5)-4554.6(0.0)-7606.6(10.5)-8909.1(0.0)-8412.8(0.0)-7860(10.0)]TJ
0 -1.0135 TD
[(Vaginal)-332.9(discharge,)-338.3(%)-13033.6(4.8)-4554.6(7.1)-8107.6(5.3)-8908.1(0.0)-7911.8(10.0)-7861(10.0)]TJ
T*
[(Previous)-331.4(pregnancies,)-341.4(%)-11259.9(39.5)-4054.6(35.7)-7607.6(41.0)-8413.8(25.0)-7907.1(40.0)-7861(40.0)]TJ
T*
[(PCOS)-333.7(diagnosis,)-335.9(%)-13281.2(16.7)-4054.6(14.3)-7607.6(15.8)-8413.8(25.0)-7907.1(10.0)-7861(20.0)]TJ
0 -1.0077 TD
[(Sterility)-333.3(or)-336(infertility,)-333.2(%)-11847.3(7.1)-4053.6(14.3)-8108.6(5.3)-8412.8(25.0)-7907.1(10.0)-7861(10.0)]TJ
0 -1.0135 TD
[(Family)-330.9(history)-335.3(of)-336(endometrial)-338.6(cancer,)-336.5(%)-5167.4(9.3)-4554.6(7.1)-7606.6(10.3)-8909.1(0.0)-7911.8(10.0)-8356.2(0.0)]TJ
T*
[(Family)-330.9(history)-335.3(of)-336(leukemia,)-338.8(%)-8737.7(23.3)-4054.6(21.4)-7607.6(20.5)-8413.8(50.0)-7907.1(10.0)-7861(20.0)]TJ
T*
[(Family)-330.9(history)-335.3(of)-336(thyroid)-335.5(diseases,)-336.9(%)-5916(27.9)-4054.6(35.7)-7607.6(28.2)-8413.8(25.0)-7907.1(40.0)-7861(40.0)]TJ
0 -1.0077 TD
[(Previous)-331.4(nonendometrial)-341.5(cancer)-333.1(diagnosis,)-335.9(%)-2679.7(15.4)-4555.6(0.0)-7606.6(16.7)-8909.1(0.0)-8412.8(0.0)-7860(25.0)]TJ
0 -1.0135 TD
[(Use)-333(of)-336(oral)-333.5(contraceptives,)-340.2(%)-9135(29.3)-4054.6(38.5)-7607.6(32.4)-8909.1(0.0)-7911.8(55.6)-7861(10.0)]TJ
T*
[(Hormone)-332.6(administration)-340.5(for)-331.2(assisted)]TJ
.9905 -1.0135 TD
[(reproductive)-338.2(technology,)-332.7(%)]TJ
20.3104 1.0135 TD
[(26.2)-4054.6(28.6)-7607.6(26.3)-8413.8(25.0)-7907.1(30.0)-7861(10.0)]TJ
-21.3008 -2.0213 TD
[(Pelvic)-336.7(pain,)-331.2(%)-15314(16.7)-4054.6(14.3)-7607.6(18.4)-8909.1(0.0)-7911.8(20.0)-7861(30.0)]TJ
0 -1.0135 TD
[(Histological)-338.2(diagnosis,)-335.9(%)]TJ
.9962 -1.0135 TD
[(AEH)-18254.6(86.0)-4054.6(64.3)-2678.3(0.008)-2679.3(94.9)]TJ
/F6 1 Tf
39.8952 0 TD
(<)Tj
/F4 1 Tf
.5528 0 TD
[(0.001)-3427.9(0.0)]TJ
/F6 1 Tf
9.3576 0 TD
(<)Tj
/F4 1 Tf
.5528 0 TD
[(0.001)-2679.3(90.0)-7360(100)]TJ
-50.3585 -1.0077 TD
[(EEC)-18410.6(14.0)-4054.6(35.7)-8108.6(5.1)-7911.8(100)-8658.1(10.0)-8356.2(0.0)]TJ
-.9962 -1.3187 TD
[(Mean)-335.4(length)-335.7(of)-330.2(therapy)-337.7(in)-330.4(months,)-338.7(SD)-4039.4(26.6)-334.6(\(23.1\))-1304(29.8)-334.6(\(26.4\))-4857(26.6)-334.6(\(23.1\))-5409.8(26.5)-334.6(\(23.4\))-5409.8(36.5)-334.6(\(28.4\))-4857(28.1)-334.6(\(30.5\))]TJ
/F8 1 Tf
0 8.7511 -8.7511 -0 472.8755 64.5165 Tm
(*)Tj
/F4 1 Tf
.5053 0 TD
-.0002 Tc
[(Ch)6.2(i-squared)-290.8(tes)5(t)-289.3(for)-285.4(categorical)-289.6(variables;)]TJ
/F5 1 Tf
17.1871 0 TD
0 Tc
(t)Tj
/F4 1 Tf
.2786 0 TD
[(-test)-287.8(and)-282.7(KruskalWallis)-289.6(test)-283.9(for)-285.2(normally)-283.5(distribut)5.6(ed)-283.9(and)-289.2(non-normally)-283.9(dis)6.4(tributed)-284.6(continuous)-283.4(variables,)-288.1(respectively.)-286.5(All)-287.8(other)]TJ
/F5 1 Tf
52.099 0 TD
(p)Tj
/F4 1 Tf
.4988 0 TD
[(-values)-281.4(that)-285.5(were)-283.6(not)]TJ
-71.4758 -1.0236 TD
[(reported)-312.8(were)]TJ
/F6 1 Tf
5.9147 0 TD
(>)Tj
/F4 1 Tf
.5507 0 TD
[(0.05.)-312.8(All)]TJ
/F5 1 Tf
3.9 0 TD
(p)Tj
/F4 1 Tf
.5053 0 TD
[(-values)-313.8(are)-308.4(referred)-318.9(to)-313.8(the)-313.9(comp)5.9(arison)-313.8(between)-313.8(the)-313.9(women)-312.6(versus)-313.4(those)-316.4(without)-307.8(the)-313.9(selected)-315.2(outcome:)-312(for)-317.6(example,)-316.5(women)-312.6(experiencing)-310.7(regression)-313.8(vers)]TJ
62.3996 0 TD
[(us)-313.4(those)-316.4(without)]TJ
-73.2703 -1.0236 TD
-.0004 Tc
(regression.)Tj
/F7 1 Tf
8.9663 0 0 8.9663 302.3999 34.2425 Tm
0 Tc
(5)Tj
ET
endstream
endobj
57 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 62.022 537.6188 Tm
0 0 0 rg
0 Tc
0 Tw
[(increased)-492.5(peripheral)-487(conversion)-485.5(of)-486(androgen)-483.4(to)-486.1(estrogens)]TJ
0 -1.1116 TD
[(in)-313.4(adipose)-321(tissue;)-314.1(this)-315.5(may)-316.7(antagonize)-321.2(the)-315.6(action)-314.5(of)-318.9(proges-)]TJ
T*
(tins.)Tj
7.3823 0 0 6.5614 78.7464 520.1006 Tm
(36,50)Tj
9.843 0 0 9.843 99.4393 515.7353 Tm
[(However,)-412.6(these)-410.9(authors)-412(did)-412.4(not)-406.6(perform)-413.2(a)-411.2(multi-)]TJ
-3.8014 -1.1174 TD
[(variate)-213(analysis)-212.6(that)-207.4(demonstrated)-213.8(the)-206.2(independen)-8.9(t)-202.8(predictive)]TJ
0 -1.1116 TD
[(value)-480.3(of)-480.2(obesity.)-478.9(Indeed,)-484.6(a)-480.3(recent)-482.5(systematic)-482.3(review)-482.2(and)]TJ
T*
[(meta-analysis)-290.9(that)-282.3(assessed)-288(its)-285.6(predictive)-285.6(value)-284.4(at)-280(multivari-)]TJ
0 -1.1174 TD
[(ate)-443.5(analysis)-443(showed)-440.4(no)-439.9(signicant)-445.4(association,)]TJ
7.3823 0 0 6.5614 254.4377 476.277 Tm
(23)Tj
9.843 0 0 9.843 266.1165 471.855 Tm
[(which)-445.4(is)]TJ
-20.7349 -1.1116 TD
[(concordant)-285.3(with)-282(our)-279.7(results.)]TJ
1.0137 -1.1116 TD
[(With)-289.2(regard)-291.1(to)-284.6(the)-292.6(type)-287.9(of)-290.1(pathology)-287.8(diagnosis,)-290.9(we)-286.5(found)]TJ
-1.0137 -1.1174 TD
[(signicantly)-326.7(more)-329.3(frequent)-328(treatment)-326(failure)-327(and)-327(no)-324.7(regres-)]TJ
0 -1.1116 TD
[(sion)-303.8(for)-308.5(a)-301.8(diagnosis)-304.7(of)-307.4(EEC)-306.2(instead)-303.8(of)-307.4(AEH,)-303.4(as)-308.4(reported)-304.9(by)]TJ
T*
[(previously)-225.3(published)-230(studies.)]TJ
7.3823 0 0 6.5614 176.2582 421.455 Tm
(18,36,50)Tj
9.843 0 0 9.843 204.3212 417.0897 Tm
[(However,)-228.3(this)-223.3(predictive)]TJ
-14.4569 -1.1116 TD
[(value)-203.8(was)-206.7(not)-199.3(independent,)-203.6(as)-204.8(shown)-202(at)-205.1(multivariate)-202.9(analy)-8(sis.)]TJ
1.0137 -1.1174 TD
[(Hormone)-408.4(administration)-416.8(for)-406.4(ART)-415.3(showed)-411.6(no)-405.4(predictive)]TJ
-1.0137 -1.1116 TD
[(value)-232.6(of)-226.8(treatment)-233.9(failure)-234.9(in)-227(our)-227.9(analysis,)-233.3(in)-232.7(contrast)-230(with)-230.2(the)]TJ
T*
[(results)-308.2(of)-307.4(another)-309.6(study)-310.7(in)-301.8(the)-309.9(literature,)-312.1(which)-307.2(showed)-308(that)]TJ
0 -1.1174 TD
[(patients)-293.6(undergoing)-294.5(ART)-294.4(were)-295.6(more)-294.8(likely)-290.4(to)-290.3(achieve)-294.7(preg-)]TJ
0 -1.1116 TD
[(nancy)-284.3(\()]TJ
/F5 1 Tf
3.1794 0 TD
(p)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.7142 0 TD
[(0.04\))-284.3(at)-285.7(multivariate)-283.5(analy)-8(sis)]TJ
7.3823 0 0 6.5614 222.633 355.6912 Tm
(33)Tj
9.843 0 0 9.843 230.0598 351.3259 Tm
[(;)-283.5(however,)-285(no)-278.7(im-)]TJ
-17.0718 -1.1116 TD
[(pact)-277.6(on)-278.7(the)-275.3(risk)-275(of)-278.6(treatment)-279.9(failure)-275.2(was)-275.8(found)-276.2(in)-278.8(that)-276.5(study,)]TJ
0 -1.1174 TD
[(which)-261.1(is)-261.3(in)-261.5(concordance)-259.8(with)-264.7(our)-256.7(results.)-265.6(The)-259.1(use)-257.7(of)-261.4(fertility)]TJ
0 -1.1116 TD
[(drugs)-373.9(\(e.g.,)-371.8(clomiphene)-378.9(citrate)-374.4(and)-373.1(gonadotropins\))-373.7(is)-370.8(asso-)]TJ
T*
[(ciated)-327.1(with)-328.1(increased)-325.5(estrogen)-327.8(production)-329.2(during)-323.5(the)-327.1(follic-)]TJ
T*
[(ular)-190(phase)-192(of)-186.5(the)-188.9(ovulation)-190(induction)-190(cycle.)]TJ
7.3823 0 0 6.5614 229.3228 300.9259 Tm
(51)Tj
9.843 0 0 9.843 238.5637 296.5605 Tm
[(Thus,)-187.4(a)-192.3(possible)]TJ
-17.9357 -1.1174 TD
[(association)-343.9(between)-346.3(fertility)-345.7(drugs)-339.3(and)-344.3(the)-344.4(risk)-338.4(of)-342(endome-)]TJ
0 -1.1116 TD
[(trial)-283.5(cancer)-281.9(has)-280.7(been)-283.2(studied,)-283.1(with)-282(conicting)-284.3(results.)]TJ
7.3823 0 0 6.5614 273.8834 278.9858 Tm
(5257)Tj
9.843 0 0 9.843 72 263.6787 Tm
[(It)-278.8(is)-284.4(interesting)-285.4(to)-278.8(note)-282.2(that)-282.3(several)-281.8(immunohistochemical)]TJ
-1.0137 -1.1174 TD
[(markers)-201.1(showed)-198.5(an)-193.4(association)-199.9(with)-195.6(the)-200.4(response)-195(of)-198(AEH)-196.3(and)]TJ
0 -1.1116 TD
[(EEC)-225.6(to)-227(conservative)-231(treatment.)]TJ
7.3823 0 0 6.5614 184.8755 246.1039 Tm
(30)Tj
9.843 0 0 9.843 194.5133 241.7385 Tm
[(Among)-226.5(these,)-224.3(estrogen)-229.9(and)]TJ
-13.4604 -1.1116 TD
[(progesterone)-247(receptors,)-247.1(Dusp6,)-240(GRP78,)-241.1(and)-246.4(mismatch)-244.1(repair)]TJ
0 -1.1174 TD
[(proteins)-395.9(showed)-400.1(a)-399.7(predictive)-395(ability)-401(on)-393.9(pretreatment)-399.6(biop-)]TJ
0 -1.1116 TD
(sies.)Tj
7.3823 0 0 6.5614 79.2567 213.222 Tm
(30)Tj
9.843 0 0 9.843 89.4047 208.8566 Tm
[(On)-273.8(the)-281.1(other)-277.5(hand,)-279.7(the)-281.1(expression)-283.8(of)-278.6(Bcl-2,)-276.2(ki67,)-278.7(and)]TJ
-2.7819 -1.1116 TD
[(surviving)-321(showed)-319.5(an)-320.1(association)-320.9(with)-316.6(the)-321.4(response)-321.7(on)-313.2(post-)]TJ
0 -1.1174 TD
[(treatment)-527.6(biopsies.)]TJ
7.3823 0 0 6.5614 139.3511 191.3385 Tm
(30)Tj
9.843 0 0 9.843 151.937 186.9165 Tm
[(It)-520.7(would)-524.9(be)-527.5(interesting)-527.3(to)-520.7(combine)]TJ
-9.1349 -1.1116 TD
[(clinical)-369.9(and)-367.3(immunohist)-7.9(ochemical)-367.4(data)-369.7(to)-370.9(improve)-367.3(the)-367.5(tai-)]TJ
T*
[(loring)-294.8(of)-290.2(treatment)-297.2(and)-292.4(follow-up)-293.2(of)-290.2(patients)-293.6(with)-293.5(AEH)-294.2(and)]TJ
T*
(EEC.)Tj
/F10 1 Tf
8.9663 0 0 8.9663 62.022 127.7858 Tm
[(Strengths)-334.1(and)-335.7(limitations)]TJ
/F4 1 Tf
9.843 0 0 9.843 72 111.3448 Tm
[(Our)-280.6(study)-281.9(has)-286.5(several)-287.6(aspects)-281.6(that)-288.1(are)-282.1(worth)-282.9(highlighting.)]TJ
-1.0137 -1.1116 TD
[(To)-239.5(the)-235(best)-241.7(of)-238.3(our)-239.4(knowledge,)-235.6(our)-239.4(study)-241.6(evaluates)-239.3(the)-240.7(largest)]TJ
T*
[(number)-446.7(of)-445.7(clinical)-444.8(factor)-452.5(\()]TJ
/F5 1 Tf
11.3178 0 TD
(n)Tj
/F6 1 Tf
.6681 0 TD
(=)Tj
/F4 1 Tf
.72 0 TD
[(23\))-446.8(in)-440.1(the)-448.1(prediction)-445.7(of)-445.7(re-)]TJ
-12.7059 -1.1174 TD
[(sponse)-260.8(to)-261.5(conservative)-265.6(management)-265.9(of)-261.4(AEH)-259.7(and)-263.7(EEC)-260.2(in)-261.5(the)]TJ
0 -1.1116 TD
[(literature.)-421.6(In)-416.9(addition,)-417(many)-415.7(risk)-413.2(factors)-418.8(are)-420.3(evaluated)-418(for)]TJ
T*
[(the)-286.8(rst)-286.4(time)-283.5(in)-290.3(this)-280.9(eld.)-291.2(Moreover,)-286.1(our)-285.5(study)-287.7(is)-284.4(among)-284.4(the)]TJ
25.504 67.9242 TD
[(larges)-8.8(t)-202.8(cohorts)-210.4(assessing)-207.4(clinical)-214.4(predictive)-210.7(factors)-211.5(of)-203.8(women)]TJ
0 -1.1174 TD
[(with)-420.2(AEH.)]TJ
7.3823 0 0 6.5614 357.392 718.5825 Tm
(58)Tj
9.843 0 0 9.843 368.9007 714.1605 Tm
[(Additionally,)-422.5(this)-424.9(is)-416.8(the)-419.3(rst)-418.8(study)-420.1(assessing)]TJ
-5.6733 -1.1116 TD
[(clinical)-393(predictive)-389.2(factors)-390(in)-388.2(women)-388.9(undergoing)-392.4(combined)]TJ
T*
[(conservativ)-9.9(e)-186.6(treatment)-187.8(with)-189.8(hysteroscopic)-190.4(resection)-192(followed)]TJ
T*
[(by)-463(LNG-IUD)-467.4(insertion.)-463.9(Such)-460.4(approach)-467.3(has)-459.3(recently)-467.5(been)]TJ
0 -1.1174 TD
[(suggested)-455.5(to)-451.6(be)-452.6(more)-456(effective)-452.5(and)-453.7(safer)-456.8(than)-449.2(other)-456(con-)]TJ
0 -1.1116 TD
[(servat)-8.8(ive)-592.1(treatment)-602.5(options)-595.3(\(e.g.,)-596.5(oral)-598.9(progestins,)-597.2(LNG-)]TJ
T*
[(IUD)-281.5(alone,)-282.1(hysteroscopic)-282.6(resection)-284.1(alone\).)]TJ
7.3823 0 0 6.5614 482.5132 652.8187 Tm
(18)Tj
9.843 0 0 9.843 492.6613 648.4534 Tm
[(Lastly,)-277.4(another)]TJ
-18.2468 -1.1174 TD
[(strength)-205.8(of)-198(our)-193.3(study)-201.3(is)-198(the)-200.4(thorough)-199(pathology)-195.7(review)-205.7(by)-198(two)]TJ
0 -1.1116 TD
[(independen)-8.9(t)-254.7(pathologists.)-254.1(This)-259(fact)-254.5(is)-255.6(crucial,)-262.5(given)-254.5(the)-258(inter)]TJ
T*
[(and)-378.8(intraobserver)-374.9(variability)-377.9(in)-376.7(the)-373.2(assessment)-378(of)-370.8(endome-)]TJ
0 -1.1174 TD
[(trial)-283.5(specimens.)]TJ
7.3823 0 0 6.5614 375.4203 608.9951 Tm
[(56,57)-7.8(,5961)]TJ
9.843 0 0 9.843 323.0361 593.6313 Tm
[(We)-472.2(acknowledge)-478.6(several)-477.6(limitations)-470.1(of)-474.5(our)-469.8(study.)-475.4(The)]TJ
-1.0137 -1.1116 TD
[(retrospectiv)-11.1(e)-336.3(study)-339.5(design)-341.8(and)-338.5(the)-338.7(overall)-344.3(small)-342(size)-340.7(of)-342(the)]TJ
T*
[(study)-253.1(population)-248.7(could)-248.7(limit)-249.2(the)-246.5(interpretation)-255.6(of)-244.1(the)-252.3(data.)-246.4(In)]TJ
0 -1.1174 TD
[(fact,)-413.4(the)-407.8(perfect)-408.7(prediction)-411.1(found)-408.7(for)-412.2(infrequent)-411(menstrual)]TJ
0 -1.1116 TD
[(bleed)-8(ing)-481.5(might)-479.3(be)-481.4(due)-482.5(to)-480.4(the)-482.6(high)-482.6(number)-487(of)-480.2(covariates)]TJ
T*
[(compared)-341.8(with)-333.8(the)-332.9(sample)-338.4(size.)-332.6(However,)-337.7(a)-336.3(greater)-333.8(sample)]TJ
0 -1.1174 TD
[(size)-231.3(and)-229.1(a)-226.9(prospective)-234.5(study)-224.3(design)-232.3(are)-230.2(difcult)-229(to)-227(obtain)-226.9(in)-227(a)]TJ
0 -1.1116 TD
[(single)-341.9(center,)-341.9(as)-337.2(only)-338.6(20%25%)-338.2(of)-336.2(endometrial)-339.7(cancer)-345.3(and)]TJ
T*
[(AEH)-346.1(occur)-341.9(in)-342.1(premenopausal)-348.4(women,)-340.5(and)-344.3(only)-338.6(3%5%)-341.7(of)]TJ
0 -1.1174 TD
[(women)-268(diagnosed)-265.6(with)-259(endometrial)-270.6(cancer)-264.7(are)-264.8(younger)-262.3(than)]TJ
0 -1.1116 TD
[(45)-284.4(years)-284.1(of)-278.6(age.)]TJ
7.3823 0 0 6.5614 376.4409 488.4093 Tm
(62)Tj
/F7 1 Tf
8.9663 0 0 8.9663 313.0582 462.1038 Tm
(Conclusion)Tj
/F4 1 Tf
9.843 0 0 9.843 323.0361 445.6629 Tm
[(Among)-232.2(the)-229.2(23)-226.8(clinical)-231.7(factors)-228.8(assessed)-230.4(in)-232.7(the)-229.2(prediction)-226.8(of)]TJ
-1.0137 -1.1116 TD
[(the)-188.9(response)-183.5(to)-180.9(conservativ)-9.9(e)-180.8(management)-185.3(of)-186.5(AEH)-184.8(and)-183(EEC,)-183(a)]TJ
T*
[(longer)-209.5(menstrual)-203.6(cycle)-210.7(and)-200.3(infrequent)-209.4(menstrual)-209.3(bleeding)-207.2(are)]TJ
0 -1.1174 TD
[(independen)-8.9(t)-300.7(predictive)-308.6(clinical)-306.6(factors)-309.4(for)-302.7(treatment)-308.7(failure.)]TJ
0 -1.1116 TD
[(Patients)-345.2(with)-339.6(those)-340.7(clinical)-341.1(features)-340.5(may)-339.8(have)-340.8(an)-343.2(increased)]TJ
T*
[(risk)-470.8(of)-468.7(treatment)-475.8(failure)-471(and)-471(might)-467.8(benet)-469.7(from)-472.1(a)-468.8(closer)]TJ
0 -1.1174 TD
[(follow-up,)-423.4(and)-424.9(a)-422.7(different)-421.3(treatment)-429.7(protocol.)-422.6(Further)-423.5(and)]TJ
0 -1.1116 TD
[(larger)-285.5(studies)-285.2(are)-282.1(necessary)-284.8(to)-278.8(conrm)-285.3(our)-279.7(ndings.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 313.0582 347.0172 Tm
[(Ethics)-340.5(Approval)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 330.5763 Tm
[(The)-380(present)-384.3(study)-379.8(received)-382.2(approval)-379.9(by)-382.3(the)-379(Institutional)]TJ
-1.0137 -1.1116 TD
[(Review)-258.6(Board)-255.3()50.8(Carlo)-256.5(Romano)52.2()-254.5(o)0(f)-249.8(the)-258(University)-255.1(of)-249.8(Naples)]TJ
T*
[(Federico)-288.7(II.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 313.0582 286.7527 Tm
[(Consent)-340.5(to)-330.2(Participate)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 270.3117 Tm
[(All)-280.9(included)-282.1(patients)-287.8(signed)-278.4(an)-285.6(informed)-282(written)-280.8(consent.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 313.0582 248.3716 Tm
[(Consent)-340.5(for)-330.9(Publication)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 231.9306 Tm
[(All)-280.9(included)-282.1(patients)-287.8(signed)-278.4(an)-285.6(informed)-282(written)-280.8(consent.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 313.0582 209.9905 Tm
[(Availability)-336.8(of)-336.6(Data)-336.2(and)-331.9(Material)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 193.5496 Tm
[(The)-293.6(datasets)-294.4(generated)-296.9(during)-294.7(and/or)-290.1(analyzed)-295.8(during)-294.7(the)]TJ
-1.0137 -1.1116 TD
[(current)-246.3(study)-247.3(are)-247.5(available)-245.3(from)-241.7(the)-246.5(corresponding)-246.9(author)-244(on)]TJ
0 -1.1174 TD
[(reasonable)-286.3(request.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 313.0582 149.726 Tm
[(Author)-338.7(Contributions)]TJ
/F4 1 Tf
9.843 0 0 9.843 323.0361 133.285 Tm
[(A.R.:)-254.1(study)-253.1(conception,)-260.1(study)-253.1(design,)-253(study)-253.1(methods,)-255.4(data)]TJ
-1.0137 -1.1116 TD
[(analy)-8(sis,)-547.9(article)-558.7(preparation,)-554.9(methods)-551.5(superv)-7.5(ision,)-550.4(whole)]TJ
0 -1.1174 TD
[(study)-546.9(supervision;)-544.3(A.T.:)-548(study)-541.1(conception,)-548.1(study)-546.9(design,)]TJ
0 -1.1116 TD
[(study)-431.7(methods,)-433.9(data)-433.1(analysis,)-434.9(article)-432(preparation,)-433.9(methods)]TJ
T*
[(superv)-7.5(ision;)-628.9(M.E.F.:)-633.1(study)-633.2(design,)-633.2(study)-633.3(methods,)-635.5(data)]TJ
0 -1.1174 TD
[(analy)-8(sis,)-306(article)-311.1(preparation;)-310.8(M.I:)-307.2(study)-304.9(design,)-310.6(study)-304.9(meth-)]TJ
0 -1.1116 TD
[(ods,)-438.5(data)-438.8(collection,)-438.9(article)-437.8(preparation)-10(;)-433.2(A.M.:)-438.3(study)-437.4(con-)]TJ
T*
[(ception,)-342(data)-340.9(collection,)-341(data)-335.2(analysis,)-342.7(responsible)-336.8(surgeon;)]TJ
ET
62.022 699.534 239.131 .28345 re
f
62.022 599.301 239.131 .28345 re
f
62.022 680.882 239.131 .22681 re
f
BT
/F9 1 Tf
9.845 0 0 9.845 79.8236 725.1588 Tm
(Table)Tj
/F4 1 Tf
3.0002 0 TD
(3.)Tj
/F9 1 Tf
1.2496 0 TD
[(Multivariate)-330.4(Analyses)-337.4(Evaluating)]TJ
-4.5147 -1.0135 TD
[(the)-338.1(Potential)-332.2(Clinical)-332.7(Factors)-334.5(As)-336.6(Predictors)]TJ
5.2057 -1.0135 TD
[(of)-331.2(Therapeutic)-338(Failure)]TJ
/F5 1 Tf
-6.749 -1.8427 TD
[(Variables)-10440(OR)-332.2(\(95%)-333.2(CI\))]TJ
/F4 1 Tf
22.9132 0 TD
(p)Tj
-22.9132 -1.8946 TD
[(Mean)-335.4(menstrual)-335.1(cycle)-336.9(length,)]TJ
.9905 -1.0135 TD
[(1-day)-334.4(increase)]TJ
12.7149 1.0135 TD
[(2.10)-334.6(\(1.034.29\))-1582(0.042)]TJ
-13.7053 -2.0212 TD
[(Histological)-338.2(diagnosis:)]TJ
1.002 -1.0135 TD
[(AEH)-334(\(ref.)-336.7(cat.\))-9655.4(1)-5327.7()]TJ
T*
[(EEC)-10809.3(4.54)-334.6(\(0.2484.4\))-1582(0.3)]TJ
-1.002 -1.313 TD
[(Infrequent)-334.9(menstrual)]TJ
.9905 -1.0135 TD
[(bleeding,)-336.5(yes)-338(vs)-330(no)]TJ
13.9414 1.0135 TD
(\(Omitted\))Tj
7.3837 0 0 6.5625 248.0314 619.9935 Tm
(a)Tj
9.845 0 0 9.845 285.1086 615.6282 Tm
()Tj
6.5633 0 0 5.8334 70.0157 591.4203 Tm
(a)Tj
8.7511 0 0 8.7511 72.9637 587.5085 Tm
[(As)-231.5(in)23(fr)18.2(eq)20.6(ue)20.6(nt)-236.1(me)23(ns)16.9(t)15.4(r)0(u)16.7(a)13(l)-243.7(b)0(l)16.6(e)13(ed)20.6(in)16.6(g)-238.5(p)0(e)20.6(r)0(f)18.2(e)0(c)19.4(t)0(l)17.8(y)-245(p)14.1(r)0(e)15.6(d)14.1(ic)15.4(t)15.4(e)0(d)-232.1(t)0(h)16.6(e)-239.7(ou)15.3(t)15.4(c)0(o)14.1(m)0(e)23(,)]TJ
-1.2503 -1.0236 TD
[(the)-339.8(variable)-340.1(was)-335.2(drop)-6.9(ped)-334.6(by)-334.5(the)-333.3(mod)-7(el.)]TJ
.9134 -1.0236 TD
-.0145 Tc
[(OR)-14.5(,)-238.7(o)6.1(dds)-251.4(ratio)6.1(;)-251.8(C)-14.5(I)12.7(,)-243.9(cond)6.1(e)-1.5(nce)-247.7(i).9(nterval;)-245.3(ref.)-250.4(cat.,)-250.4(refe)4.9(rence)-247.7(categ)6.1(ory.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
0 Tc
(6)Tj
46.2711 0 TD
[(RAFFONE)-336.8(ET)-338.7(AL.)]TJ
ET
endstream
endobj
61 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.843 0 0 9.843 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(M.G.:)-328.9(study)-322.2(conception,)-329.2(data)-329.4(analysis,)-325.5(responsible)-331.1(surgeon,)]TJ
0 -1.1174 TD
[(methods)-384.4(supervision;)-388.7(L.I.:)-380.1(study)-385.6(conception,)-381.1(data)-387(analysis,)]TJ
0 -1.1116 TD
[(responsible)-503.9(pathologist,)-500.9(whole)-497.2(study)-500.8(supervision;)-498.2(A.D.S.:)]TJ
T*
[(study)-443.2(conception,)-450.2(data)-444.6(analysis,)-446.4(responsible)-446.3(surgeon,)-444.1(arti-)]TJ
T*
[(cle)-276.5(preparation,)-278.4(whole)-278.4(study)-270.4(supervision;)-279.3(J.C.:)-276.1(study)-270.4(design)-7.7(,)]TJ
0 -1.1174 TD
[(da)13.9(ta)-251.2(an)19.7(al)19.5(ys)21(is)15.1(,)-256.9(a)0(r)14(t)0(i)20.6(c)0(l)19.6(e)-261.4(pr)20.9(ep)13.9(ar)19.7(at)19.5(io)20.7(n,)-252.2(me)18.4(th)20.7(od)20.8(s)-265.8(s)0(u)21(p)0(e)19.7(r)0(v)20.9(i)0(s)15.1(i)0(o)20.7(n)0(,)-252.2(w)0(h)20(o)0(l)20.7(e)]TJ
0 -1.1116 TD
[(study)-247.3(s)-6.7(upervi)-7.9(sion;)-247.5(F.Z.:)-247.5(study)-247.3(conce)-9(ption,)-245.3(st)-7.9(udy)-245.2(design)-7.7(,)-239.6(data)]TJ
T*
[(analy)-8(sis,)-421.2(respon)-7.5(sible)-421.4(surgeo)-7.5(n,)-419.2(methods)-419(s)-6.7(upervi)-7.9(sion,)-416.7(whole)]TJ
0 -1.1174 TD
[(study)-287.7(superv)-7.5(ision.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 615.5715 Tm
[(Author)-338.7(Disclosure)-336.7(Statement)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 599.1306 Tm
[(No)-279.5(competing)-284.4(nancial)-283.1(interests)-288.7(exist.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 577.1904 Tm
[(Funding)-340.9(Information)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 560.7495 Tm
[(No)-279.5(funding)-284.3(was)-281.6(received)-284.3(for)-279.7(this)-280.9(article.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 538.866 Tm
[(Supplementary)-341.9(Material)]TJ
/F4 1 Tf
9.843 0 0 9.843 69.7323 522.425 Tm
[(Supplementary)-284.1(Data)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 500.4849 Tm
(References)Tj
/F4 1 Tf
9.2951 0 0 9.2951 64.4031 484.4408 Tm
[(1.)-500.4(Kurman)-508.7(RJ,)-510.5(Carcangiu)-508.4(ML,)-507.7(Herrington)-510.9(CS,)-508.2(Young)-508.5(RH)]TJ
1.2503 -1.1284 TD
[(\(Eds\).)-341.9(WHO)-337.3(classication)-340.8(of)-332(tumours)-336.9(of)-338.1(female)-338.1(reproduc-)]TJ
0 -1.1223 TD
[(tive)-339.1(organs.)-329.8(4th)-335.3(ed.)-333.9(Lyon,)-331.9(France:)-341.5(IARC;)-330.8(2014.)]TJ
-1.2503 -1.1284 TD
[(2.)-500.4(Lacey)-362.9(JV,)-354.8(Sherman)-355.8(ME,)-361.4(Rush)-352.1(BB,)-357.6(et)-357.7(al.)-357.7(Absolute)-358.7(risk)-355.2(of)]TJ
1.2503 -1.1223 TD
[(endometrial)-532.8(carcinoma)-531.8(during)-527.1(20-year)-526.4(follow-up)-524.8(among)]TJ
0 -1.1284 TD
[(women)-359.8(with)-354.8(endometrial)-355.9(hyperplasia.)-356.1(J)-353(Clin)-358(Oncol.)-353.7(2010;)]TJ
0 -1.1223 TD
(28\(5\):78892.)Tj
-1.2503 -1.1284 TD
[(3.)-500.4(Gallos)-456(ID,)-455.6(Alazzam)-463.7(M,)-450.8(Clark)-456.7(TJ,)-458.8(et)-455.3(al.)-455.3(Management)-455.7(of)]TJ
1.2503 -1.1223 TD
[(endometrial)-282.8(hyperplasia)-282.9(green-top)-276.1(guideline)-282.5(no.)-274.8(67)-280.9(RCOG/)]TJ
0 -1.1284 TD
-.0192 Tc
[(BSGE)-338.4(joi)5.6(n)-1(t)-342(g)5.1(uid)5.1(e)-5.2(l)5.6(i)-.5(ne)-340.7(\(February)-336.5(2)-1(0)5.1(16\).)-336.4(A)-2.6(ccessed)-342.6(A)3.5(ugu)5.1(st)-335.9(08,)]TJ
0 -1.1223 TD
0 Tc
[(202)24(0)-311.2(f)0(r)13.4(o)0(m)-304.8(h)0(t)18.6(t)0(p)12.5(s)0(:)19.5(/)0(/)13.1(w)0(w)14.9(w)16.6(.r)15.8(co)13.8(g)18.2(.or)21.7(g)18.2(.uk)24(/g)12.5(lo)18.6(ba)13.8(la)14.4(ss)13.7(et)14.4(s/)19.5(doc)19.8(um)18.4(en)13.8(ts)13.4(/)]TJ
0 -1.1284 TD
.0487 Tc
[(guidelines/green-t)6.4(op-gu)5.9(idelines/g)5.9(tg_67_endo)5.9(metrial_)]TJ
T*
0 Tc
[(hy)-6.4(perplasi)-9.9(a.pdf)]TJ
-1.2503 -1.1223 TD
[(4.)-500.4(Travaglino)-324(A,)-325.1(Raffone)-323.8(A,)-319(Saccone)-325.7(G,)-319(et)-321.1(al.)-321.1(Loss)-324(of)-319.8(B-cell)]TJ
1.2503 -1.1284 TD
[(lymphoma)-339.4(2)-335.6(immunohistochemical)-343.9(expression)-339.2(in)-335.2(endome-)]TJ
0 -1.1223 TD
[(trial)-334.9(hyperplasia:)-343.4(a)-333.7(specic)-338.3(marker)-336.8(of)-332(precancer)-338(and)-334(novel)]TJ
0 -1.1284 TD
[(indication)-513.8(for)-505.2(treatment:)-507.7(a)-510.6(systematic)-510.3(review)-512.7(and)-504.8(meta-)]TJ
0 -1.1223 TD
[(a)14(n)0(a)26(l)18.7(ys)25(i)18.7(s)12.9(.)-317.2(A)0(c)24.4(t)18.7(a)-321.5(O)16.6(bs)25(t)18.7(e)14(t)-316.7(G)0(y)28.6(n)0(e)26(c)14(o)18.2(l)-322.8(S)15.3(c)14(a)14(n)18.2(d.)-305.2(2)18.2(0)0(1)30.2(8)0(;)24.7(9)18.2(7\()27.9(1)18.2(2)0(\))27.9(:)12.6(1)18.2(4)0(1)30.2(5)0()30.2(2)0(6)30.2(.)]TJ
-1.2503 -1.1284 TD
[(5.)-500.4(Travaglino)-433.8(A,)-422.6(Raffone)-433.6(A,)-422.6(Saccone)-435.5(G,)-422.6(et)-430.9(al.)-424.8(Endometrial)]TJ
1.2503 -1.1223 TD
[(hyperplasia)-459.7(and)-462.1(risk)-452.8(of)-460(coexistent)-456.7(cancer:)-464.8(WHO)-459.3(vs)-456.8(EIN)]TJ
0 -1.1284 TD
[(criteria.)-340(Histopathology.)-334.1(2019;74\(5\):67687.)]TJ
-1.2503 -1.1223 TD
[(6.)-500.4(Travaglino)-446(A,)-440.9(Raffone)-445.8(A,)-447(Saccone)-441.6(G,)-447(et)-443.1(al.)-443.1(Congruence)]TJ
1.2503 -1.1284 TD
[(between)-466(1994)-458(WHO)-459.3(classication)-468.9(of)-460(endometrial)-459.6(hyper-)]TJ
0 -1.1223 TD
.0185 Tc
[(p)-6(l).6(asia)-400.6(an)-6(d)-390.3(e)-4.1(nd)-6(ometri)-5.5(al)-395.8(in)-6(traep)-6(ith)-6(el)-5.5(ial)-395.8(n).1(eopl)-5.5(as)-5.2(ia)-394.5(s)-5.1(y).1(st)-5.5(em.)]TJ
0 -1.1284 TD
.0194 Tc
[(Am)-474.3(J)-473.9(C)-3.8(li)-4.6(n)-474.8(P)4.2(ath)-5.1(o)1(l.)-474.7(20)-5.1(19;)-474.2([Epu)-5.1(b)-474.8(a)2.9(head)-474.8(of)-477.1(print)-4.6(])-1.4(;)-474.2(DOI:)]TJ
0 -1.1223 TD
.019 Tc
[(1)-5.5(0.10)-5.5(93/aj)-5(cp/)-5(a)-3.6(qz132.)]TJ
-1.2503 -1.1284 TD
0 Tc
[(7.)-500.4(Raffone)-384.8(A,)-386(Travaglino)-385(A,)-386(Saccone)-386.7(G,)-379.9(et)-388.2(al.)-382.1(PAX2)-384.8(in)-384(en-)]TJ
1.2503 -1.1223 TD
[(dometrial)-485.6(carcinogenesis)-492.1(and)-486.5(in)-481.5(differential)-488.7(diagnosis)-484.4(of)]TJ
0 -1.1284 TD
[(endometrial)-484(hyperplasia.)-484.2(A)-477.4(systematic)-479.8(review)-482.2(and)-480.4(meta-)]TJ
0 -1.1223 TD
[(an)19.9(al)14.4(ys)18.9(i)12.6(s)-255.4(of)-252.7(di)24.7(ag)19.9(no)18(st)19.5(ic)-247.9(ac)15.7(cu)19.9(ra)17.6(cy)19.9(.)-256.2(A)0(c)18.3(t)0(a)-247.9(O)0(b)16.4(s)12.9(te)20.5(t)-261.8(G)0(y)22.5(n)0(e)19.9(c)0(o)13.8(l)-255.7(Sc)23.1(an)13.8(d.)]TJ
0 -1.1284 TD
-.0184 Tc
[(2)-18.4(0)-.4(1)-18.4(9)-.4(;)-5.8(9)-18.4(8\()-18.4(3\))-18.4(:2)-18.4(8)5.7(7)-18.4(9)-18.4(9.)]TJ
-1.2503 -1.1223 TD
0 Tc
[(8.)-500.4(Raffone)-323.8(A,)-312.9(Travaglino)-317.9(A,)-319(Saccone)-319.6(G,)-319(et)-315(al.)-321.2(Loss)-317.9(of)-313.7(PTEN)]TJ
1.2503 -1.1284 TD
[(expression)-351.4(as)-345.2(diagnostic)-348.8(marker)-342.9(of)-350.3(endometrial)-343.7(precancer:)]TJ
0 -1.1223 TD
[(a)-467.9(systematic)-473.7(review)-470(and)-474.3(meta-analysis.)-468.5(Acta)-473.5(Obstet)-468.2(Gy-)]TJ
0 -1.1284 TD
[(necol)-337.9(Scand.)-335.4(2019;98\(3\):27586.)]TJ
-1.2503 -1.1223 TD
[(9.)-500.4(Travaglino)-317.9(A,)-312.9(Raffone)-311.6(A,)-312.9(Saccone)-319.6(G,)-312.9(et)-308.9(al.)-315.1(Complexity)-313.3(of)]TJ
1.2503 -1.1284 TD
[(glandular)-401.2(architecture)-403.8(should)-402(be)-394.8(reconsidered)-406(in)-396.2(the)-400.5(clas-)]TJ
0 -1.1223 TD
.0194 Tc
[(s)-4.2(i)1.5(cat)-4.6(ion)-462.6(a)2.9(nd)-462.6(management)-455.9(o)-5.1(f)]TJ
13.4 0 TD
.0202 Tc
[(end)-4.3(o)1.8(metri)-3.8(a)3.7(l)-461.2(hyperpl)-3.8(a)3.7(s)-3.4(i)2.3(a.)]TJ
-13.4 -1.1284 TD
.0184 Tc
[(APM)-5.4(I)-2.4(S.)-335.4(20)-6.1(19;)-5.6(127\(6)-6.1(\))3.7(:)-5.6(427)-6.1(34.)]TJ
-1.7505 -1.1223 TD
0 Tc
[(10.)-500.5(Travaglino)-360.6(A,)-355.5(Raffone)-360.4(A,)-355.5(Saccone)-362.3(G,)-355.5(et)-357.7(al.)-357.7(PTEN)-356.5(immu-)]TJ
1.7505 -1.1284 TD
[(nohistochemistry)-588(in)-579.1(endometrial)-581.6(hyperplasia:)-587.4(which)-579.3(are)]TJ
27.0135 70.9158 TD
[(the)-272.4(optimal)-271.4(criteria)-272.9(for)-267.3(the)-272.4(diagnosis)-277.1(of)-264.9(precancer?)-281.4(APMIS.)]TJ
0 -1.1223 TD
(2019;127\(4\):16169.)Tj
-1.7505 -1.1284 TD
[(11.)-500.5(Raffone)-427.5(A,)-428.7(Travaglino)-427.7(A,)-428.7(Saccone)-429.4(G,)-428.7(et)-424.8(al.)-430.9(Endometrial)]TJ
1.7505 -1.1223 TD
[(hyperplasia)-313.4(and)-309.6(progression)-313.1(to)-310.8(cancer:)-312.4(which)-310.9(classication)]TJ
0 -1.1283 TD
[(system)-398.7(straties)-401.8(the)-400.5(risk)-404(better?)-399.1(A)-398.2(systematic)-406.6(review)-403(and)]TJ
0 -1.1223 TD
[(meta-analysis.)-242.9(Arch)-246.5(Gynecol)-242.2(Obstet.)-242.6(2019;299\(5\):123342.)]TJ
-1.7505 -1.1284 TD
[(12.)-500.5(Raffone)-512.9(A,)-508(Travaglino)-519.2(A,)-508(Saccone)-514.8(G,)-514.1(et)-510.2(al.)-516.3(PTEN)-509(ex-)]TJ
1.7505 -1.1223 TD
[(pression)-414(in)-408.4(endometrial)-416.9(hyperplasia)-417.1(and)-413.3(risk)-416.2(of)-411.3(cancer:)-416(a)]TJ
0 -1.1284 TD
[(systematic)-254.1(review)-262.7(and)-254.7(meta-analysis.)-261.2(Arch)-252.7(Gynecol)-260.5(Obstet.)]TJ
0 -1.1223 TD
(2019;299\(6\):151124.)Tj
-1.7505 -1.1284 TD
[(13.)-500.5(Sherman)-477.8(ME.)-483.3(Theories)-482(of)-484.4(endometrial)-484(carcinogenesis:)-485.6(a)]TJ
1.7505 -1.1223 TD
[(multidisciplinary)-440.9(approach.)-443.1(Mod)-438.8(Pathol.)-439.9(2000;13\(3\):295)]TJ
0 -1.1284 TD
(308.)Tj
-1.7505 -1.1284 TD
[(14.)-500.5(Ferlay)-422.6(J,)-420.2(Soerjomataram)-426.8(I,)-423.4(Dikshit)-426.9(R,)-419.7(et)-424.8(al.)-424.8(Cancer)-423.1(inci-)]TJ
1.7505 -1.1223 TD
[(dence)-641.6(and)-639(mortality)-645.5(worldwide:)-643.7(sources,)-638.3(methods)-643.8(and)]TJ
0 -1.1284 TD
[(major)-378.3(patterns)-375.8(in)-377.9(GLOBOCAN)-380.4(2012.)-372.7(Int)-380.3(J)-371.3(Cancer.)-380.5(2015;)]TJ
0 -1.1223 TD
(136\(5\):E35986.)Tj
-1.7505 -1.1284 TD
[(15.)-500.5(Reed)-459(SD,)-456.2(Newton)-452.9(KM,)-458.6(Clinton)-455.4(WL,)-457.9(et)-455.3(al.)-461.4(Incidence)-459(of)]TJ
1.7505 -1.1223 TD
-.0156 Tc
[(end)-15.6(o)14.6(metr)-15.6(i)12.9(a)-1.6(l)-283.5(h)-15.6(y)14.6(p)-15.6(e)10.4(r).2(plasia.)-284(A)1(m)-283.7(J)-283.2(Ob)-15.6(s)15.5(t)-3(et)-283.5(Gy)-15.6(n)14.6(eco)-15.6(l)15.2(.)-284(20)-15.6(0)8.5(9)2.6(;20)-15.6(0)14.6(\(6)-15.6(\))12.3(:)]TJ
0 -1.1284 TD
0 Tc
[(6)18.2(7)0(8)30.2(.)0(e)26.1(1)18.2(6)30.2(.)]TJ
-1.7505 -1.1223 TD
[(16.)-500.5(Raffone)-256.7(A,)-258(Travaglino)-256.9(A,)-258(Saccone)-264.7(G,)-251.9(et)-260.1(al.)-260.2(Management)-260.5(of)]TJ
1.7505 -1.1284 TD
[(women)-329.3(with)-330.4(atypical)-329.2(polypoid)-329.4(adenomyoma)-330.4(of)-332(the)-327.3(uterus:)]TJ
0 -1.1223 TD
.0197 Tc
[(a)-454.3(q)1.3(u)-4.8(a)3.2(n)-4.8(tit)-4.3(at)-4.3(ive)-460.4(s)2.1(y)-4.8(s)2.1(temat)-4.3(i)1.8(c)-454.3(r)-1.1(evi)-4.3(e)3.2(w.)-456.1(Act)-4.3(a)-454.3(Obs)-4(t)1.8(et)-455.6(Gynecol)]TJ
0 -1.1284 TD
-.0303 Tc
[(Scand.)-286.5(20)-6(19;)-286([Epub)-286.6(ahead)-286.6(o).1(f)-288.9(p).1(ri)-5.5(nt];)-286(DOI:)-286(1).1(0)-6(.1111/aogs.13553.)]TJ
-1.7505 -1.1223 TD
0 Tc
[(17.)-500.5(Chandra)-352(V,)-349.5(Kim)-354.7(JJ,)-352.3(Benbrook)-354(DM,)-348.9(et)-357.7(al.)-351.6(Therapeutic)-356.9(op-)]TJ
1.7505 -1.1284 TD
[(tions)-468.3(for)-468.6(management)-468.2(of)-472.2(endometrial)-471.8(hyperplasia.)-472(J)-468.9(Gy-)]TJ
0 -1.1223 TD
[(necol)-331.8(Oncol.)-335.4(2016;27\(1\):e8.)]TJ
-1.7505 -1.1284 TD
[(18.)-500.5(Giampaolino)-357.1(P,)-356.9(Di)-355(Spiezio)-358.8(Sardo)-357.8(A,)-355.5(Mollo)-358.7(A,)-355.5(et)-357.7(al.)-357.7(Hys-)]TJ
1.7505 -1.1223 TD
[(teroscopic)-465.7(endometrial)-471.8(focal)-462.2(resection)-471.6(followed)-465.6(by)-463.8(levo-)]TJ
0 -1.1284 TD
[(norgestrel)-268.6(intrauterine)-272.9(device)-275.2(insertion)-267.5(as)-272(a)-266.6(fertility-sparing)]TJ
0 -1.1223 TD
[(treatment)-544.7(of)-545.4(atypical)-548.8(endometrial)-551.1(hyperplasia)-545.1(and)-547.5(early)]TJ
0 -1.1284 TD
[(endometrial)-246.2(cancer:)-245.3(a)-248.3(retrospective)-246.4(study.)-243.3(J)-243.2(Minim)-248.5(Invasive)]TJ
0 -1.1223 TD
[(Gynecol.)-333.8(2019;26\(4\):64856.)]TJ
-1.7505 -1.1284 TD
[(19.)-500.5(Colombo)-328.1(N,)-325.1(Creutzberg)-334(C,)-328.3(Amant)-328.8(F,)-326.4(et)-333.3(al.)-327.3(ESMO-ESGO-)]TJ
1.7505 -1.1223 TD
[(ESTRO)-422.4(consensus)-421.8(conference)-429.7(on)-421.1(endometrial)-423(cancer:)-428.2(di-)]TJ
0 -1.1284 TD
[(agnosis,)-356.7(treatment)-355.7(and)-358.4(follow-up.)-354.1(Ann)-355.8(Oncol.)-359.8(2016;27\(1\):)]TJ
0 -1.1223 TD
(1641.)Tj
-1.7505 -1.1284 TD
[(20.)-500.5(Yuk)-380.2(JS,)-380.5(Song)-387.7(JY,)-379.2(Lee)-388.9(JH,)-379.2(et)-382.1(al.)-388.2(Levonorgestrel-releasing)]TJ
1.7505 -1.1223 TD
[(intrauterine)-407.1(systems)-410.2(versus)-408.2(oral)-403(cyclic)-408.8(medroxyprogester-)]TJ
0 -1.1284 TD
[(one)-498.7(acetate)-502.7(in)-493.7(endometrial)-502.3(hyperplasia)-502.4(therapy:)-504.8(a)-498.4(meta-)]TJ
0 -1.1223 TD
[(analysis.)-336.1(Ann)-331.4(Surg)-335.1(Oncol.)-335.4(2017;24\(5\):13229.)]TJ
-1.7505 -1.1284 TD
[(21.)-500.5(Gallos)-340.1(ID,)-339.7(Yap)-341.7(J,)-340.9(Rajkhowa)-344.7(M,)-341(et)-339.4(al.)-339.5(Regression,)-344.1(relapse,)]TJ
1.7505 -1.1223 TD
[(and)-334(live)-339.1(birth)-331.3(rates)-339.4(with)-336.5(fertility-sparing)-339.1(therapy)-340.5(for)-334.4(endo-)]TJ
0 -1.1284 TD
[(metrial)-497.5(cancer)-501.9(and)-498.7(atypical)-500(complex)-502.5(endometrial)-502.3(hyper-)]TJ
0 -1.1223 TD
[(plasia:)-317.9(a)-321.5(systematic)-321.2(review)-323.7(and)-315.7(metaanalysis.)-325.8(Am)-318.6(J)-322.5(Obstet)]TJ
0 -1.1284 TD
[(Gynecol.)-333.8(2012;207\(4\):266.e112.)]TJ
-1.7505 -1.1284 TD
[(22.)-500.5(Raffone)-336(A,)-337.2(Travaglino)-342.3(A,)-337.3(Saccone)-337.9(G,)-337.2(et)-339.4(al.)-333.4(Diabetes)-342.7(mel-)]TJ
1.7505 -1.1223 TD
[(litus)-516.6(and)-510.9(responsiveness)-519.1(of)-521(endometrial)-514.5(hyperplasia)-520.7(and)]TJ
0 -1.1284 TD
[(early)-358.5(endometrial)-355.9(cancer)-361.6(to)-353.5(conservative)-360.4(treatment.)-355.7(Gyne-)]TJ
0 -1.1223 TD
[(col)-254.1(Endocrinol.)-258.9(2019;)-250.2([Epub)-255(ahead)-257.3(of)-258.8(print];)-254(DOI:)-255.6(10.1080/)]TJ
0 -1.1284 TD
(09513590.2019.1624716.)Tj
-1.7505 -1.1223 TD
[(23.)-500.5(Koskas)-425.7(M,)-420.3(Uzan)-425.3(J,)-426.3(Luton)-422.9(D,)-422.6(et)-424.8(al.)-424.8(Prognostic)-429.7(factors)-427.4(of)]TJ
1.7505 -1.1284 TD
[(oncologic)-514.8(and)-510.9(reproductive)-518(outcomes)-520(in)-512(fertility-sparing)]TJ
0 -1.1223 TD
[(management)-370.6(of)-368.6(endometrial)-374.2(atypical)-371.9(hyperplasia)-374.4(and)-370.6(ade-)]TJ
0 -1.1284 TD
[(nocarcinoma:)-428(systematic)-437.1(review)-427.3(and)-431.6(meta-analysis.)-431.9(Fertil)]TJ
0 -1.1223 TD
[(Steril.)-331.9(2014;101\(3\):78594.)]TJ
-1.7505 -1.1284 TD
[(24.)-500.5(Travaglino)-458.2(A,)-465.3(Raffone)-464.1(A,)-459.2(Saccone)-459.9(G,)-465.3(et)-461.4(al.)-461.4(PTEN)-460.2(as)-461(a)]TJ
1.7505 -1.1223 TD
[(predictive)-520.9(marker)-525.8(of)-521(response)-522.5(to)-518.1(conservative)-525.1(treatment)]TJ
0 -1.1284 TD
[(in)-438.9(endometrial)-441.3(hyperplasia)-441.4(and)-437.7(early)-443.9(endometrial)-441.3(cancer.)]TJ
0 -1.1223 TD
[(A)-379.9(systematic)-388.3(review)-390.8(and)-382.8(meta-analysis.)-389.2(Eur)-382.8(J)-383.5(Obstet)-388.9(Gy-)]TJ
9.2951 0 0 9.2951 327.118 97.5118 Tm
[(necol)-331.8(Reprod)-335.4(Biol.)-333.6(2018;231:10410.)]TJ
-1.7505 -1.1223 TD
[(25.)-500.5(Sato)-507.2(M,)-505.7(Arimoto)-503.5(T,)-508.3(Kawana)-510.7(K,)-501.9(et)-510.2(al.)-504.1(Measurement)-512.2(of)]TJ
1.7505 -1.1284 TD
[(endometrial)-453.5(thickness)-452(by)-445.5(transvaginal)-453.2(ultrasonography)-452.4(to)]TJ
0 -1.1223 TD
[(predict)-394.9(pathological)-396.3(response)-394.4(to)-396.2(medroxyprogesterone)-396.7(ac-)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(PREDICTIVE)-341.6(FACTORS)-336.8(IN)-335.1(CONSERVATIVELY)-339.1(TREATED)-338(AEH)-332.3(AND)-337.2(EEC)-19757.7(7)]TJ
ET
endstream
endobj
68 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2951 0 0 9.2951 78.2929 725.1588 Tm
0 0 0 rg
.0114 Tc
0 Tw
[(etate)-444.3(i)-.4(n)-446.2(p)-.9(ati)11.4(e)-4.7(nts)-445.3(w)-2.5(i)11.4(t)-6(h)-446.2(g)-.9(rade)-450.4(1)-446.2(e)1(n)5.2(dom)11.4(etrioid)-446.2(a)1(d)5.2(e)1(nocarci-)]TJ
0 -1.1223 TD
.0118 Tc
[(no)5.6(ma.)-329.8(M).2(ol)-329.3(Cli)11.8(n)-341.7(Oncol)11.8(.)-341.6(2)5.6(0)-.5(1)5.6(6)-.5(;4)5.6(\(4)5.6(\):49)5.6(26)5.6(.)]TJ
-1.7505 -1.1284 TD
0 Tc
[(26.)-500.5(Travaglino)-586.3(A,)-581.2(Raffone)-586.1(A,)-581.2(Saccone)-581.9(G,)-581.2(et)-583.3(al.)-583.4(Immuno-)]TJ
1.7505 -1.1223 TD
[(histochemical)-411.6(nuclear)-411.8(expression)-412.4(of)]TJ
/F11 1 Tf
15.2908 0 TD
(b)Tj
/F4 1 Tf
.5489 0 TD
[(-catenin)-411.4(as)-412.3(a)-406.9(surro-)]TJ
-15.8397 -1.1283 TD
[(gate)-386.6(of)-393(CTNNB1)-387.5(exon)-389(3)-390.5(mutation)-387.5(in)-384(endometrial)-392.5(cancer.)]TJ
0 -1.1223 TD
[(Am)-336.9(J)-328.6(Clin)-339.7(Pathol.)-330.2(2019;151\(5\):52938.)]TJ
-1.7505 -1.1284 TD
[(27.)-500.5(Penner)-539(KR,)-537.4(Dorigo)-540.9(O,)-538.5(Aoyama)-541.1(C.)-535.6(et)-540.6(al.)-540.7(Predictors)-539.9(of)]TJ
1.7505 -1.1223 TD
.0102 Tc
[(resolution)-551.1(o)-2.1(f)-547.3(c)-.2(om)10.2(p)-8(l)-1.6(ex)-551.1(at)10.2(y)-7.8(p)-2.1(i)10.2(c)-5.9(a)-6.3(l)-544.4(hyperplasia)-549.2(or)-553.4(grade)-555.3(1)]TJ
0 -1.1284 TD
.0107 Tc
[(endomet)10.7(r)-9.6(i)10.7(a)-11.5(l)-586.6(a).3(denocarcinoma)-585.3(in)-587.2(prem)10.7(e)-5.6(nopausal)-586.6(w)2.9(omen)]TJ
0 -1.1223 TD
0 Tc
[(t)-11.8(r)-8.6(e)-10.4(a)-10.4(t)-11.8(e)-10.4(d)-262.4(wi)17(t)12.6(h)-244.1(pr)15.7(og)24.1(es)14.7(t)12.6(i)0(n)-231.5(t)0(h)18.6(e)0(r)17.6(a)0(p)19.9(y)0(.)-232(G)0(y)16.4(n)0(e)19.9(c)0(o)19.9(l)-243.5(On)16.4(co)19.9(l)12.6(.)-244(20)18(12)18(;)12.6(1)0(2)18(4)0(\()21.8(3)0(\))15.7(:)]TJ
0 -1.1284 TD
[(54)18(2)24.1(8.)]TJ
-1.7505 -1.1223 TD
[(28.)-500.5(Travaglino)-439.9(A,)-434.8(Raffone)-439.7(A,)-434.8(Saccone)-441.6(G,)-434.8(et)-437(al.)-437(Nuclear)-443.9(ex-)]TJ
1.7505 -1.1284 TD
[(pression)-304.2(of)]TJ
/F11 1 Tf
4.7757 0 TD
(b)Tj
/F4 1 Tf
.5489 0 TD
[(-catenin)-307.7(in)-304.7(endometrial)-313.3(hyperplasia)-307.3(as)-302.5(marker)]TJ
-5.3246 -1.1284 TD
[(of)-460(premalignancy.)-464.8(APMIS.)-461.1(2019;)-457.6([Epub)-462.4(ahead)-458.6(of)-460(print];)]TJ
0 -1.1223 TD
[(DOI:)-334.8(10.1111/apm.12988.)]TJ
-1.7505 -1.1284 TD
[(29.)-500.5(Raffone)-433.6(A,)-434.8(Travaglino)-433.8(A,)-428.7(Saccone)-435.5(G,)-434.8(et)-430.9(al.)-430.9(Should)-430.1(pro-)]TJ
1.7505 -1.1223 TD
[(gesterone)-240.5(and)-236.4(estrogens)-241.5(receptors)-236.7(be)-236.3(assessed)-242(for)-236.8(predicting)]TJ
0 -1.1284 TD
[(the)-376.1(response)-376.1(to)-377.9(conservative)-378.7(treatment)-374(of)-374.7(endometrial)-380.3(hy-)]TJ
0 -1.1223 TD
[(perplasia)-630.2(and)-632.9(cancer?)-634.3(A)-629.9(systematic)-632.3(review)-628.6(and)-632.9(meta-)]TJ
0 -1.1284 TD
[(analysis.)-336.1(Acta)-339.3(Obstet)-334(Gynecol)-333.7(Scand.)-335.4(2019;98\(8\):97687.)]TJ
-1.7505 -1.1223 TD
[(30.)-500.5(Travaglino)-586.3(A,)-581.2(Raffone)-586.1(A,)-581.2(Saccone)-581.9(G,)-581.2(et)-583.3(al.)-583.4(Immuno-)]TJ
1.7505 -1.1284 TD
[(hi)18.6(s)12.9(t)0(o)18.6(c)0(h)19.9(e)0(m)14.2(i)12.6(ca)15.7(l)-237.4(p)0(r)21.8(e)0(d)19.9(i)0(c)20.5(t)0(i)19.2(v)0(e)-230.2(m)12.5(ar)17.6(ke)19.9(rs)-227.4(of)-228.3(re)17.6(sp)18.9(on)18(s)12.9(e)-242.2(t)12.6(o)-238(co)19.9(ns)18.9(er)17.6(va)19.9(t)12.6(i)0(v)18.6(e)]TJ
0 -1.1223 TD
[(t)12.6(r)0(e)17.6(a)0(t)14.4(m)12.5(en)19.9(t)-353.3(o)0(f)-338.1(e)0(n)19.9(d)0(o)18(m)12.5(et)14.4(ri)22.4(al)-339.4(hy)18(pe)19.9(rp)15.7(l)12.6(a)0(s)20.8(i)0(a)-345.5(a)14(nd)-341.8(ea)15.7(rl)22.4(y)-353.9(e)14(nd)18(om)18.4(et)20.5(ri)16.3(a)14(l)]TJ
0 -1.1284 TD
[(cance)-11.5(r:)-392.4(a)-394.7(syste)-8.7(matic)-397.9(revie)-10.9(w.)-392.1(Acta)-400.3(Obstet)-401.1(Gynec)-10.7(ol)-390.1(Sc)-7.4(and.)]TJ
0 -1.1223 TD
[(2019)-6.7(;98\(9\):108)-11(699.)]TJ
-1.7505 -1.1284 TD
.0113 Tc
[(3)11.3(1)11.3(.)-489.2(Raffo)5.1(n)-1(e)-230.9(A)-2.6(,)-232.7(T)-2.9(ravag)5.1(lin)5.1(o)-238.9(A)3.5(,)-232.7(S)2.2(acco)5.1(ne)-237(G,)-232.7(et)-238.3(al.)-232.7(D)3.5(iagn)5.1(osti)11.3(c)-242.7(a).9(nd)]TJ
1.7505 -1.1223 TD
.0119 Tc
[(prog)5.7(no)5.7(stic)-236.4(v)5.7(a)1.5(lue)-236.4(o)5.7(f)-240.6(A)4.1(RID1)5.7(A)-239.9(i)11.9(n)-244(e)1.5(nd)5.7(omet)11.9(r)-8.4(i)11.9(a)-10.3(l)-231.6(hy)5.7(perplasi)11.9(a:)-237.7(a)]TJ
0 -1.1284 TD
.0192 Tc
[(no)-5.3(vel)-565.9(m)1.2(arker)-562.7(o).8(f)-562.7(o).8(ccult)-559.8(cancer.)-560.3(APM)-4.6(I)-1.6(S.)-560.3(20)-5.3(19;)-4.8(127\(9)-5.3(\))4.5(:)]TJ
0 -1.1223 TD
.0184 Tc
[(59)-6.1(760)-6.1(6.)]TJ
-1.7505 -1.1284 TD
0 Tc
[(32.)-500.5(Raffone)-342.1(A,)-337.3(Travaglino)-336.2(A,)-337.3(Saccone)-337.9(G,)-337.3(et)-339.4(al.)-339.4(Diabetes)-336.6(mel-)]TJ
1.7505 -1.1223 TD
[(litus)-461.7(is)-456.3(associated)-466.7(with)-458.4(occult)-459.5(cancer)-465.3(in)-457.2(endometrial)-465.7(hy-)]TJ
0 -1.1284 TD
[(perplasia.)-368(Pathol)-366.7(Oncol)-365.8(Res.)-368.5(2019;)-366.1([Epub)-364.8(ahead)-373.2(of)-362.5(print];)]TJ
0 -1.1223 TD
[(DOI:)-334.8(10.1007/s12253-019-00684-3.)]TJ
-1.7505 -1.1284 TD
[(33.)-500.5(Zhou)-441.6(R,)-438(Yang)-445.5(Y,)-440.9(Lu)-435.2(Q,)-440.9(et)-443.1(al.)-443.1(Prognostic)-441.9(factors)-439.6(of)-441.8(on-)]TJ
1.7505 -1.1223 TD
[(cological)-573.3(and)-565.8(reproductive)-572.9(outcomes)-568.8(in)-566.9(fertility-sparing)]TJ
0 -1.1284 TD
[(treatment)-428.8(of)-429.6(complex)-429.3(atypical)-426.8(hyperplasia)-429.3(and)-431.6(low-grade)]TJ
0 -1.1223 TD
[(endometrial)-246.2(cancer)-245.7(using)-249.3(oral)-244.4(progestin)-243.7(in)-243.7(Chinese)-244.5(patients.)]TJ
0 -1.1284 TD
[(Gynecol)-333.7(Oncol.)-335.4(2015;139\(3\):4248.)]TJ
-1.7505 -1.1223 TD
[(34.)-500.5(Fukui)-405.6(Y,)-404.3(Taguchi)-413.3(A,)-404.3(Adachi)-406.7(K,)-410.4(et)-406.5(al.)-406.5(Polycystic)-406.6(ovarian)]TJ
1.7505 -1.1284 TD
[(morphology)-289.4(may)-284.8(be)-291.2(a)-284.9(positive)-289.4(prognostic)-292.6(factor)-287.8(in)-286.4(patients)]TJ
0 -1.1223 TD
[(with)-318.2(endometrial)-319.3(cancer)-318.9(who)-313.1(achieved)-322.4(complete)-317.2(remission)]TJ
0 -1.1284 TD
[(after)-415.7(fertility-sparing)-418.4(therapy)-413.7(with)-415.8(progestin.)-414.5(Asian)-413.7(Pac)-414.3(J)]TJ
0 -1.1223 TD
[(Cancer)-337.8(Prev.)-333.3(2017;18\(11\):31116.)]TJ
-1.7505 -1.1284 TD
[(35.)-500.5(Burleigh)-359(A,)-349.5(Talhouk)-354.2(A,)-355.6(Gilks)-354(CB,)-357.6(McAlpine)-356.9(JN.)-354.8(Clinical)]TJ
1.7505 -1.1223 TD
[(and)-346.2(pathological)-353.6(characterization)-357.4(of)-350.3(endometrial)-349.8(cancer)-355.5(in)]TJ
0 -1.1284 TD
[(young)-372.8(women:)-383.8(identication)-374.4(of)-380.8(a)-376.4(cohort)-372.8(without)-379(classical)]TJ
T*
[(risk)-336.9(factors.)-335.9(Gynecol)-333.7(Oncol.)-335.4(2015;138\(1\):1416.)]TJ
-1.7505 -1.1223 TD
[(36.)-500.5(Yang)-421.1(YF,)-425.7(Liao)-426.9(YY,)-424.4(Liu)-422.6(XL,)-424.7(et)-418.7(al.)-424.8(Prognostic)-423.6(factors)-427.4(of)]TJ
1.7505 -1.1284 TD
[(regression)-292.7(and)-285.2(relapse)-295.1(of)-289.3(complex)-289(atypical)-292.6(hyperplasia)-289(and)]TJ
0 -1.1223 TD
[(well-differentiated)-561.8(endometrioid)-559.3(carcinoma)-562.3(with)-556(conser-)]TJ
0 -1.1284 TD
[(vative)-337.5(treatment.)-337.4(Gynecol)-333.7(Oncol.)-335.4(2015;139\(3\):41923.)]TJ
-1.7505 -1.1223 TD
[(37.)-500.5(Yang)-518.7(B,)-511.2(Xie)-518(L,)-514.4(Zhang)-519.2(H,)-514.1(et)-516.3(al.)-516.3(Insulin)-519.7(resistance)-517.8(and)]TJ
1.7505 -1.1284 TD
[(overweight)-238.3(prolonged)-232.9(fertility-sparing)-241.5(treatment)-239.8(duration)-238.3(in)]TJ
0 -1.1223 TD
[(endometrial)-252.3(atypical)-256(hyperplasia)-258.5(patients.)-251(J)-249.3(Gynecol)-254.4(Oncol.)]TJ
0 -1.1284 TD
(2018;29\(3\):e35.)Tj
-1.7505 -1.1223 TD
[(38.)-500.5(Von)-374.1(Elm)-367.3(E,)-374.2(Altman)-371(DG,)-369.5(Egger)-375.1(M,)-371.5(et)-369.9(al.)-369.9(The)-372.5(strengthen-)]TJ
1.7505 -1.1284 TD
[(ing)-353.6(the)-351.7(reporting)-356.7(of)-350.3(observational)-355.8(studies)-356.1(in)-347.4(epidemiology)]TJ
0 -1.1223 TD
[(\(STROBE\))-590.8(statement:)-583.8(guidelines)-592.8(for)-584.5(reporting)-582.3(observa-)]TJ
0 -1.1284 TD
[(tional)-332.7(studies.)-337.8(Int)-331.5(J)-334.7(Surg.)-335.2(2014;12\(12\):14959.)]TJ
-1.7505 -1.1223 TD
[(39.)-500.5(Kalogera)-474.5(E,)-471.7(Dowdy)-467.4(SC,)-471.6(Bakkum-Gamez)-477.7(JN.)-470.7(Preserving)]TJ
1.7505 -1.1284 TD
[(fertility)-318.3(in)-316.9(young)-317.9(patients)-318(with)-318.2(endometrial)-319.4(cancer:)-318.4(current)]TJ
0 -1.1223 TD
[(perspectives.)-341.3(Int)-331.5(J)-334.7(Womens)-331.4(Health.)-339.1(2014;6:691701.)]TJ
25.2569 68.6469 TD
[(40.)-500.5(Sanderson)-288.5(PA,)-285.4(Critchley)-289.6(HOD,)-285.8(Williams)-286.7(ARW,)-291.8(et)-284.5(al.)-284.6(New)]TJ
1.7505 -1.1223 TD
[(concepts)-353.9(for)-352.7(an)-352.1(old)-347.5(problem:)-353.8(the)-345.6(diagnosis)-356.3(of)-350.3(endometrial)]TJ
0 -1.1284 TD
[(hyperplasia.)-337.8(Hum)-337(Reprod)-335.4(Update.)-333.6(2017;23\(2\):23254.)]TJ
-1.7505 -1.1223 TD
[(41.)-500.5(Baak)-251.6(JP,)-246.3(Mutter)-243.4(GL.)-247.8(EIN)-250.2(and)-242.5(WHO94.)-252.3(J)-243.2(Clin)-248.2(Pathol.)-244.8(2005;)]TJ
1.7505 -1.1283 TD
(58\(1\):16.)Tj
-1.7505 -1.1223 TD
[(42.)-500.5(Shan)-379.7(BE,)-373(Ren)-375.4(YL,)-375.9(Sun)-375.4(JM,)-376.9(et)-376(al.)-376(A)-373.8(prospective)-380.5(study)-371.3(of)]TJ
1.7505 -1.1284 TD
[(fertility-sparing)-296.4(treatment)-288.6(with)-287.7(megestrol)-290.1(acetate)-289.3(following)]TJ
0 -1.1223 TD
[(hy)18(st)19.5(er)17.6(os)18.9(co)19.9(pi)18.6(c)-321.5(c)0(u)19.9(r)0(e)17.6(t)12.6(ta)14.4(ge)-309.5(fo)21.8(r)-325.7(w)0(e)18.3(l)12.6(l-)16.3(di)18.6(ff)19.5(e)14(r)0(e)17.6(n)0(t)18.6(i)12.6(at)14.4(ed)-309.5(en)19.9(do)18(m)12.5(e)0(t)14.4(r)0(i)22.4(o)0(i)18.6(d)]TJ
0 -1.1284 TD
[(ca)-8.7(rcinoma)-266.9(and)-266.9(atypical)-268.2(hyp)-6.5(erplasi)-9.7(a)-260.5(i)0(n)-262(young)-263(patients)-13.1(.)-262.3(Arch)]TJ
0 -1.1223 TD
[(Gy)-8(necol)-337.9(Obstet)-10.7(.)-329.4(2)0(0)-6.4(13;288)-6.4(\(5\):111523.)]TJ
-1.7505 -1.1284 TD
[(43.)-500.5(Haoula)-528.7(Z,)-520.5(Salman)-523.5(M,)-524(Atiomo)-519.3(W.)-523(Evaluating)-528.5(the)-522.5(asso-)]TJ
1.7505 -1.1223 TD
[(ciation)-440.7(between)-435.5(endometrial)-441.3(cancer)-440.9(and)-431.6(polycystic)-440.3(ovary)]TJ
0 -1.1284 TD
[(syndrome.)-335.8(Hum)-337(Reprod.)-335.5(2012;27\(5\):1327.)]TJ
-1.7505 -1.1284 TD
[(44.)-500.5(Patel)-309.7(BG,)-311.7(Rudnicki)-307.9(M,)-310.5(Yu)-306.8(J,)-304.3(et)-308.9(al.)-309(Progesterone)-313.2(resistance)]TJ
1.7505 -1.1223 TD
[(in)-365.7(endometriosis:)-362(origins,)-367.3(consequences)-362.6(and)-364.5(interventions.)]TJ
0 -1.1284 TD
[(Acta)-339.4(Obstet)-334(Gynecol)-339.8(Scand.)-329.3(2017;96\(6\):62332.)]TJ
-1.7505 -1.1223 TD
[(45.)-500.5(Li)-361.5(X,)-361.6(Feng)-361.4(Y,)-355.5(Lin)-361.6(JF,)-356.1(et)-363.8(al.)-357.7(Endometrial)-365.8(progesterone)-359.1(re-)]TJ
1.7505 -1.1284 TD
[(sistance)-340.2(and)-334(PCOS.)-336.1(J)-334.7(Biomed)-332.1(Sci.)-336.4(2014;21\(1\):2.)]TJ
-1.7505 -1.1223 TD
[(46.)-500.5(Shen)-398(ZQ,)-394.2(Zhu)-392.7(HT,)-394.2(Lin)-392.1(JF.)-392.7(Reverse)-398(of)-393(progestin-resistant)]TJ
1.7505 -1.1284 TD
[(atypical)-524.4(endometrial)-520.6(hyperplasia)-520.7(by)-518.7(metformin)-520.5(and)-523.1(oral)]TJ
0 -1.1223 TD
[(contraceptives.)-340(Obstet)-340.1(Gynecol.)-333.8(2008;112\(2)-332.6(Pt)-332(2\):4657.)]TJ
-1.7505 -1.1284 TD
[(47.)-500.5(Savaris)-421.8(RF,)-416.7(Groll)-412.1(JM,)-419.6(Young)-411(SL,)-419.9(et)-412.6(al.)-418.7(Progesterone)-416.9(re-)]TJ
1.7505 -1.1223 TD
[(sistance)-437.8(in)-432.8(PCOS)-433.6(endometrium:)-436.9(a)-431.3(microarray)-440.9(analysis)-433.6(in)]TJ
0 -1.1284 TD
[(clomiphene)-439.4(citrate-treated)-440.2(and)-437.7(articial)-437.7(menstrual)-436.5(cycles.)]TJ
0 -1.1223 TD
[(J)-334.7(Clin)-333.6(Endocrinol)-338.1(Metab.)-337.3(2011;96\(6\):173746.)]TJ
-1.7505 -1.1284 TD
[(48.)-500.5(Park)-473.5(JY,)-470.7(Kim)-470.6(DY,)-467.1(Kim)-470.6(JH,)-470.7(et)-473.6(al.)-467.5(Long-term)-474.6(oncologic)]TJ
1.7505 -1.1223 TD
-.0137 Tc
[(o)-13.7(u)16.5(tco)-13.7(m)16.9(es)-372.8(after)-369.9(f)2.1(ertil)5(ity)4.5(-sp)-13.7(a)12.3(ri)5(n)-13.7(g)-355.5(man)-13.7(a)12.3(g)4.5(e).3(men)4.5(t)-373.1(u)4.5(s)-.8(in)4.5(g)-373.7(o)4.5(ral)-373.1(p)-13.7(r)14.2(o)4.5(-)]TJ
0 -1.1284 TD
0 Tc
[(g)-6.2(estin)-362.7(for)-358.8(you)-6.5(ng)-360.1(women)-359.8(wi)-7.4(th)-359.6(endometr)-10.9(ial)-357.2(ca)-8.7(ncer)-359(\(KGOG)]TJ
0 -1.1223 TD
[(2)-6.2(002\).)-338.4(Eur)-334(J)-334.7(Cancer.)-343.9(2013)-6.7(;49\(4\):868)-11(74.)]TJ
-1.7505 -1.1284 TD
[(49.)-500.5(Chen)-552.4(M,)-548.4(Jin)-554(Y,)-550.7(Li)-550.5(Y,)-550.7(et)-546.8(al.)-552.9(Oncologic)-553(and)-547.5(reproduc-)]TJ
1.7505 -1.1223 TD
[(tive)-339.1(outcomes)-331(after)-336.5(fertility-sparing)-339.1(management)-334(with)-336.5(oral)]TJ
0 -1.1284 TD
[(progestin)-377.8(for)-377.1(women)-372(with)-379.2(complex)-374.4(endometrial)-380.3(hyperpla-)]TJ
0 -1.1223 TD
[(sia)-411.8(and)-407.2(endometrial)-404.7(cancer.)-410.4(Int)-404.7(J)-407.9(Gynaecol)-411.2(Obstet.)-407.2(2016;)]TJ
0 -1.1284 TD
(132\(1\):348.)Tj
-1.7505 -1.1223 TD
[(50.)-500.5(Gunderson)-411.1(CC,)-412.5(Fader)-410.8(AN,)-406.1(Carson)-413.8(KA,)-406.1(Bristow)-416.3(RE.)-409.6(On-)]TJ
1.7505 -1.1284 TD
[(cologic)-362(and)-352.3(reproductive)-359.4(outcomes)-361.4(with)-354.8(progestin)-353.5(therapy)]TJ
9.2951 0 0 9.2951 329.329 348.6046 Tm
[(in)-396.2(women)-390.3(with)-391.4(endometrial)-398.6(hyperplasia)-392.7(and)-395(grade)-389.6(1)-390.5(ade-)]TJ
T*
[(nocarcinoma:)-415.8(a)-413(systematic)-412.7(review.)-415.2(Gynecol)-413(Oncol.)-414.7(2012;)]TJ
0 -1.1223 TD
(125\(2\):47782.)Tj
-1.7505 -1.1284 TD
[(51.)-500.5(Sovino)-497.2(H,)-495.8(Sir-Petermann)-495.3(T,)-496.1(Devoto)-494(L.)-490(Clomiphene)-501(cit-)]TJ
1.7505 -1.1223 TD
[(rate)-260.8(and)-260.8(ovulation)-253.9(induction.)-260(Reprod)-262.2(Biomed)-252.8(Online.)-261.7(2002;)]TJ
0 -1.1284 TD
(4\(3\):303.)Tj
-1.7505 -1.1223 TD
[(52.)-500.5(Althuis)-500.1(MD,)-495.2(Moghissi)-491.5(KS,)-498.9(Westhoff)-494.7(CL,)-495(et)-498(al.)-491.9(Uterine)]TJ
1.7505 -1.1284 TD
[(cancer)-337.2(after)-330.4(use)-327(of)-332(clomiphene)-329.7(citrate)-337.5(to)-329.1(induce)-325.9(ovulation.)]TJ
0 -1.1223 TD
[(Am)-336.9(J)-334.7(Epidemiol.)-334.7(2005;161\(7\):60715.)]TJ
-1.7505 -1.1284 TD
.8412 Tc
[(5)841.2(3)841.2(.)340.7(S)819.9(i)817.2(l)823.3(v)822.8(aI)820.4(d)822.8(o)816.7(sS)826(,W)818.4(a)824.7(r)820.4(kP)819.9(A)821.2(,)5.5(M)817.4(c)824.7(C)818(o)822.8(r)820.4(m)817.1(a)824.7(c)818.6(kV)821.2(A)821.2(,)5.5(e)818.6(t)-.1(a)818.6(l)823.3(.)]TJ
1.7505 -1.1284 TD
.0188 Tc
[(O)-7.3(vulati)-5.2(on-s)-4.8(t).9(i)-5.2(m).8(ul)-5.2(at)-5.2(ion)-268(d).4(ru)-5.7(gs)-267.1(and)-268(c)-3.8(an)-5.7(cer)-270.3(r)-2(is)-4.9(ks:)-267.4(a)-272.2(lon)-5.7(g).4(term)]TJ
0 -1.1223 TD
[(fo)-5.7(llo)-5.7(w-up)-255.8(of)-258.1(a)-253.9(B)-4.4(riti)-5.2(sh)-255.8(coh)-5.7(o).4(rt.)-255.7(B)-4.4(r)-252(J)-261(Cancer.)-255.7(2)-5.7(009;)-5.2(100)-5.7(\(1)-5.7(1\):)]TJ
0 -1.1284 TD
.0184 Tc
[(1)-6.1(824)-6.1(31.)]TJ
-1.7505 -1.1223 TD
.0202 Tc
[(5)20.2(4)20.2(.)-480.3(Jensen)-522.8(A,)-522.7(Sharif)-525.1(H,)-522.7(Kjaer)-525.1(S)5(K)-5.9(.)-522.7(Use)-527(o)1.8(f)-525.1(f)-.6(ertility)-522.8(drugs)]TJ
1.7505 -1.1284 TD
.0204 Tc
[(and)-418.9(r)-.4(isk)-412.8(o)2(f)-415.1(u)-4.1(terine)-417(cancer:)-418.3(results)-411.9(f)-.3(rom)-412.4(a)-417(large)-417(D).4(anish)]TJ
0 -1.1223 TD
.0182 Tc
[(p)-6.3(opul)-5.8(at)-5.8(io)-6.3(n-b)12(a)7.8(s)6.7(e)7.8(d)-482.1(c)7.8(o)5.9(h)12(o)5.9(r)9.6(t)-481.5(s)6.8(t)18.2(u).2(d)12(y)5.9(.)-482(A)10.4(m)-481.6(J)-481.2(E)10.1(p)5.9(i)18.2(d).2(e)7.8(m)6.3(i)6.4(o)12(l)6.4(.)-475.9(2)5.9(0)5.9(0)12(9)5.9(;)]TJ
0 -1.1284 TD
.0123 Tc
[(170)6.1(\(1)6.1(1\):1)6.1(408)6.1(1)6.1(4.)]TJ
-1.7505 -1.1223 TD
0 Tc
[(55.)-500.5(Dor)-266.6(J,)-261.6(Lerner-Geva)-266.7(L,)-258.3(Rabinovici)-263(J,)-261.6(et)-266.2(al.)-260.2(Cancer)-264.6(incidence)]TJ
1.7505 -1.1284 TD
[(in)-512(a)-510.6(cohort)-513.1(of)-508.8(infertile)-512.2(women)-512.3(who)-514.3(underwent)-507.1(in)-512.1(vitro)]TJ
0 -1.1223 TD
[(fertilization.)-339(Fertil)-337.9(Steril.)-331.9(2002;77\(2\):324.)]TJ
-1.7505 -1.1284 TD
[(56.)-500.5(Gilks)-372.3(CB,)-363.7(Oliva)-371.3(E,)-368.1(Soslow)-369.8(RA.)-366.6(Poor)-365.7(interobserver)-373.2(repro-)]TJ
1.7505 -1.1223 TD
[(ducibility)-405.3(in)-396.2(the)-400.5(diagnosis)-399(of)-399.1(high-grade)-398.2(endometrial)-404.7(car-)]TJ
0 -1.1284 TD
[(cinoma.)-337.7(Am)-336.9(J)-328.6(Surg)-335.1(Pathol.)-336.3(2013;37\(6\):87481.)]TJ
-1.7505 -1.1223 TD
[(57.)-500.5(Hoang)-433.5(LN,)-436.9(McConechy)-432.7(MK,)-434.2(Kobel)-432.9(M,)-432.5(et)-430.9(al.)-437(Histotype-)]TJ
1.7505 -1.1284 TD
[(genotype)-460.4(correlation)-456.3(in)-457.2(36)-451.6(high-grade)-459.2(endometrial)-453.5(carci-)]TJ
0 -1.1223 TD
[(nomas.)-339.2(Am)-330.8(J)-334.7(Surg)-335.2(Pathol.)-336.3(2013;37\(9\):142132.)]TJ
/F7 1 Tf
8.9663 0 0 8.9663 62.022 749.6502 Tm
(8)Tj
46.2711 0 TD
[(RAFFONE)-336.8(ET)-338.7(AL.)]TJ
ET
endstream
endobj
72 0 obj
<>stream
DNLDJD+AdvPSMP10 qh
AdvPSMP10 C ߵ}Ebo=g{}`hkVX/Y+3mig Ev]yhD].n=K:Ufypo]]l1i
endstream
endobj
75 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
9.2951 0 0 9.2951 59.7543 725.1588 Tm
0 0 0 rg
0 Tc
0 Tw
[(58.)-500.5(Guillon)-318(S,)-308.1(Popescu)-316.4(N,)-312.9(Phelippeau)-314.7(J,)-310.4(Koskas)-315.9(M.)-310.5(A)-312.8(system-)]TJ
1.7505 -1.1223 TD
[(atic)-556.8(review)-555.4(and)-547.5(meta-analysis)-559.9(of)-551.5(prognostic)-554.9(factors)-555.4(for)]TJ
0 -1.1284 TD
[(remission)-449.7(in)-445(fertility-sparing)-448.9(management)-449.9(of)-447.8(endometrial)]TJ
0 -1.1223 TD
[(atypical)-426.8(hyperplasia)-429.3(and)-419.4(adenocarcinoma.)-431.2(Int)-423(J)-426.2(Gynaecol)]TJ
0 -1.1283 TD
[(Obstet.)-340.1(2019;146\(3\):27788.)]TJ
-1.7505 -1.1223 TD
[(59.)-500.5(Guan)-256.4(H,)-258(Semaan)-253.8(A,)-258(Bandyopadhyay)-257.2(S,)-253.2(et)-254(al.)-254.1(Prognosis)-260.3(and)]TJ
1.7505 -1.1284 TD
[(reproducibility)-305.1(of)-295.4(new)-305.1(and)-297.4(existing)-301.6(binary)-299.6(grading)-299.7(systems)]TJ
0 -1.1223 TD
[(for)-419.8(endometrial)-416.9(carcinoma)-422(compared)-418.2(to)-414.5(FIGO)-417.6(grading)-421.7(in)]TJ
0 -1.1284 TD
[(hysterectomy)-246(specimens.)-236.9(Int)-240(J)-237.1(Gynecol)-236.1(Cancer.)-246.3(2011;21\(4\):)]TJ
0 -1.1223 TD
(65460.)Tj
-1.7505 -1.1284 TD
[(60.)-500.5(Han)-469.8(G,)-459.2(Sidhu)-466.6(D,)-465.3(Duggan)-464.1(MA,)-464.7(et)-461.4(al.)-467.5(Reproducibility)-466.2(of)]TJ
1.7505 -1.1223 TD
[(histological)-293.1(cell)-294.5(type)-290.9(in)-286.4(high-grade)-294.5(endometrial)-288.9(carcinoma.)]TJ
0 -1.1284 TD
[(Mod)-335.1(Pathol.)-336.3(2013;26\(12\):1594604.)]TJ
-1.7505 -1.1284 TD
.0198 Tc
[(6)19.8(1)19.8(.)-480.7(M)-4(c)3.3(Clu)-4.7(ggage)-387.1(WG.)-382.8(M)-4(y)-382.9(a)-2.8(ppro)-4.7(a)3.3(ch)-382.9(t)-4.2(o)-382.9(t)-4.2(h)1.4(e)-387.1(i)1.9(n)-4.7(t)1.9(erpret)-4.2(atio)-4.7(n)-382.9(o)1.4(f)]TJ
1.7505 -1.1223 TD
.0191 Tc
[(end)-5.4(o).7(metri)-4.9(a)2.6(l)-297.6(b).7(iop)-5.4(s)1.5(i)-4.9(e)2.6(s)-297.3(a)2.6(n)-5.4(d)-292.1(curet)-4.9(t)1.2(i)-4.9(ngs)-4.5(.)-292(J)-291.2(Cli)-4.9(n)-292.1(Pat)-4.9(hol)-4.9(.)-292(200)-5.4(6;)]TJ
0 -1.1284 TD
.0188 Tc
[(5)-5.7(9).4(\(8\):8)-5.7(011)-5.7(2.)]TJ
25.263 16.8827 TD
0 Tc
[(62.)-500.5(Soliman)-531.1(PT,)-529.7(Oh)-532.5(JC,)-528.8(Schmeler)-536.4(KM,)-531.8(et)-534.6(al.)-528.5(Risk)-534.5(factors)]TJ
1.7505 -1.1223 TD
[(for)-303.9(young)-305.7(premenopausal)-305.8(women)-311(with)-306(endometrial)-307.2(cancer.)]TJ
0 -1.1284 TD
[(Obstet)-334(Gynecol.)-333.8(2005;105\(3\):57580.)]TJ
9.843 0 0 9.843 438.803 659.9053 Tm
[(Address)-331.9(correspondence)-343.5(to:)]TJ
/F5 1 Tf
1.198 -1.1116 TD
[(Antonio)-331.7(Travaglino,)-338.1(MD)]TJ
-.3283 -1.1116 TD
[(Anato)-6.8(mic)-333.8(Pathology)-335.1(Unit)]TJ
-8.4668 -1.1174 TD
[(Department)-337.7(of)-336.4(Advanced)-336(Biomedical)-338.4(Sciences)]TJ
5.5236 -1.1116 TD
[(University)-337.9(of)-330.6(Naples)-337(Federico)-341.7(II)]TJ
7.7468 -1.1116 TD
[(Naples)-337.1(80138)]TJ
3.7726 -1.1174 TD
(Italy)Tj
-14.9407 -2.6322 TD
(Email:)Tj
/F4 1 Tf
3.0642 0 TD
(antonio.travaglino.ap@gmail.com)Tj
/F7 1 Tf
8.9663 0 0 8.9663 59.7543 749.7069 Tm
[(PREDICTIVE)-341.6(FACTORS)-336.8(IN)-335.1(CONSERVATIVELY)-339.1(TREATED)-338(AEH)-332.3(AND)-337.2(EEC)-19757.7(9)]TJ
ET
endstream
endobj
79 0 obj
<>stream
8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0
b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup`
E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn
6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O(
l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~>
endstream
endobj
80 0 obj
<>stream
hޤT{P^Y^~Z"`bs@h5